View Filing Data

Print Document View Excel Document

Document And Entity Information	12 Months Ended
Document And Entity Information	Dec. 31, 2014 shares
Document Information [Line Items]
Entity Registrant Name	FLAMEL TECHNOLOGIES SA
Entity Central Index Key	0001012477
Current Fiscal Year End Date	--12-31
Trading Symbol	FLML
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	40,191,264
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2014
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 39,760	$ 6,636
Marketable securities	53,074	401
Accounts receivable (net of allowance of $144 and $127 at December 31, 2013 and 2014 respectively)	1,679	6,204
Inventory	6,729	2,410
Research and development tax credit receivable current portion	5,932	14,139
Prepaid expenses and other current assets	4,418	2,481
Total current assets from continuing operations	111,592	32,271
Total current assets from Assets held for sale	730	1,352
Goodwill	18,491	18,491
Property and equipment, net	1,776	2,391
Intangible assets, net	28,389	40,139
Other assets:
Income tax deferred charge	13,102
Research and development tax credit receivable less current portion	0	6,410
Other long-term assets from continuing operations	125	154
Total long-term assets from continuing operations	61,883	67,585
Total long term from assets held for sale	0	15,044
Total assets including "assets held for sale"	174,205	116,252
Current liabilities:
Current portion of long-term debt	42,332	19,194
Current portion of capital lease obligations	13	16
Accounts payable	8,024	5,099
Deferred revenue	1,336	1,264
Advances from customers	0	116
Accrued expenses	5,667	6,527
Other current liabilities	5,659	7,478
Income tax payable	7,643	0
Total current liabilities from continuing operations	70,674	39,694
Total current liabilities from liabilities held for sale	168	901
Long-term debt, less current portion	76,135	66,320
Capital lease obligations, less current portion	0	15
Deferred tax liabilities	0	2,806
Other long-term liabilities	2,333	8,314
Total long-term liabilities from continuing operations	78,468	77,455
Total long-term liabilities from liabilities held for sale	0	7,714
Shareholders' equity :
Ordinary shares: 25,612,5500 issued and outstanding at December 31, 2013 and 40,191,264 at December 31, 2014 (shares authorised 52,683,254) at nominal value of 0.122 euro	6,188	3,746
Additional paid-in capital	346,582	211,473
Accumulated deficit	(320,452)	(235,546)
Accumulated other comprehensive income (loss)	(7,423)	10,815
Total shareholders' equity	24,895	(9,512)
Total Liabilities and shareholder's equity including held for sale	$ 174,205	$ 116,252

CONSOLIDATED BALANCE SHEETS [Parenthetical] $ in Thousands	Dec. 31, 2014 USD ($) shares	Dec. 31, 2014 € / shares	Dec. 31, 2013 USD ($) shares	Dec. 31, 2013 € / shares
Allowance for accounts receivable (in dollars) \| $	$ 127		$ 144
Common stock, par value (in euro per share) \| € / shares		€ 0.122		€ 0.122
Common stock, shares authorized	52,683,254		34,379,690
Common stock, shares issued	40,191,264		25,612,550
Common stock, shares outstanding	40,191,264		25,612,550

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue:
License and research revenue	$ 2,782	$ 3,026	$ 6,724
Product sales and services	11,920	983	560
Other revenues	73	170	250
Total revenue	14,775	4,179	7,534
Costs and expenses:
Cost of products and services sold	(3,383)	(562)	(400)
Research and development	(17,298)	(15,966)	(14,558)
Selling, general and administrative	(15,698)	(13,216)	(14,153)
Fair value remeasurement of acquisition liabilities, incl. related parties	(57,491)	(28,135)	18,834
Impairment of assets	0	0	(7,170)
Amortisation of intangible R&D assets	(11,749)		0
Acquisition note expenses, incl. related parties	(3,013)		0
Total	(108,632)	(57,879)	(17,447)
Income (loss) from operations	(93,857)	(53,700)	(9,913)
Interest expense	(5,747)	(2,602)	(118)
Interest expense on debt related to the royalty agreement with related parties	(3,525)	(1,990)	0
Interest income	963	254	640
Foreign exchange gain (loss)	11,871	(288)	(180)
Other Income	(36)	573	102
Income (loss) before income taxes	(90,331)	(57,753)	(9,469)
Income tax	1,407	11,244	4,729
Net income (loss) from continuing operations	(88,924)	(46,509)	(4,740)
Net income from discontinued operations	4,018	3,584	1,512
Net income (loss)	$ (84,906)	$ (42,925)	$ (3,228)
Earnings (loss) per ordinary share (basic)
Continuing operations	$ (2.45)	$ (1.83)	$ (0.19)
Discontinued operations	0.11	0.14	0.06
Net income (loss)	(2.34)	(1.69)	(0.13)
Earnings (loss) per share (diluted):
Continuing operations	(2.45)	(1.83)	(0.19)
Discontinued operations	0.11	0.14	0.06
Net income (loss)	$ (2.34)	$ (1.69)	$ (0.13)
Weighted average number of shares outstanding (in thousands) :
Basic (in shares)	36,214	25,450	25,135
Diluted (in shares)	36,214	25,450	25,135

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net loss	$ (84,906)	$ (42,925)
Other comprehensive income (loss):
Net foreign currency translation gain (loss)	(18,040)	561
Unrealized gain (loss) on Marketable Securities	(198)
Other comprehensive income (loss), net of tax	(18,238)	561
Comprehensive loss	$ (103,144)	$ (42,364)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2011	$ 29,794	$ 3,641	$ 205,489	$ (189,393)	$ 10,057
Balance (in shares) at Dec. 31, 2011		24,962,250
Subscription of warrants	5		5
Issuance of ordinary shares on exercise of stock options or warrants	601	$ 31	570
Issuance of ordinary shares on exercise of stock options or warrants (in shares)		195,000
Issuance of ordinary shares on vesting of free shares	0	$ 42	(42)
Issuance of ordinary shares on vesting of free shares (in shares)		258,150
Stock-based compensation expense	3,136		3,136
Net loss	(3,228)			(3,228)
Other comprehensive income (loss)	196				196
Comprehensive loss	(3,032)
Balance at Dec. 31, 2012	30,504	$ 3,714	209,158	(192,621)	10,253
Balance (in shares) at Dec. 31, 2012		25,415,400
Subscription of warrants	(27)		(27)
Issuance of ordinary shares on exercise of stock options or warrants	399	$ 8	391
Issuance of ordinary shares on exercise of stock options or warrants (in shares)		50,000
Issuance of ordinary shares on vesting of free shares	0	$ 24	(24)
Issuance of ordinary shares on vesting of free shares (in shares)		147,150
Stock-based compensation expense	1,975		1,975
Net loss	(42,925)			(42,925)
Other comprehensive income (loss)	561				562
Comprehensive loss	(42,364)
Balance at Dec. 31, 2013	(9,512)	$ 3,746	211,473	(235,546)	10,815
Balance (in shares) at Dec. 31, 2013		25,612,550
Subscription of warrants	351		351
Issuance of ordinary shares on capital raise	115,232	$ 2,099	113,133
Issuance of ordinary shares on capital raise (in shares)		12,400,000
Issuance of ordinary shares to Recipharm AB	13,050	$ 156	12,894
Issuance of ordinary shares to Recipharm AB (in shares)		1,026,364
Issuance of ordinary shares on exercise of stock options or warrants	6,025	$ 164	5,861
Issuance of ordinary shares on exercise of stock options or warrants (in shares)		1,001,750
Issuance of ordinary shares on vesting of free shares	0	$ 24	(24)
Issuance of ordinary shares on vesting of free shares (in shares)		150,600
Stock-based compensation expense	2,893		2,893
Net loss	(84,906)			(84,906)
Other comprehensive income (loss)	(18,238)				(18,238)
Comprehensive loss	(103,144)
Balance at Dec. 31, 2014	$ 24,895	$ 6,188	$ 346,581	$ (320,452)	$ (7,423)
Balance (in shares) at Dec. 31, 2014		40,191,264

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income (loss)	$ (84,906)	$ (42,925)	$ (3,228)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation of property and equipment and intangible assets	14,141	3,062	3,183
Loss (gain) on disposal of property and equipment	(4,952)	14	(37)
Unrealized exchange gain	(6,252)	0	0
Gains on sales of marketable securities	0	0	(6)
Grants recognized in other income and income from operations	(589)	(676)	(975)
Remeasurement of acquisition liabilities and royalty agreements (Note 21)	60,503	28,135	(18,834)
Interest expenses on debt related to the royalty agreement including related party (Note 24)	3,319	1,990	0
Impairment of assets (Note 13)	0	0	7,170
Calculated interest on amortized method	0	712	0
Change in deferred tax (Note 19)	(2,806)	(11,320)	(4,758)
Stock compensation expense (Note 7)	2,690	2,029	3,040
Increase (decrease) in cash from:
Accounts receivable	3,426	(511)	2,610
Inventory (Note 10)	(3,112)	(2,186)	176
Prepaid expenses and other current assets (Note 11)	(2,330)	315	800
Research and development tax credit receivable	13,210	665	(6,642)
Accounts payable	1,092	1,318	(613)
Deferred revenue	(55)	(14)	(4,984)
Accrued expenses	(265)	1,211	(742)
Other current liabilities	6,998	(517)	(682)
Other long-term assets and liabilities	(10,730)	(1,977)	1,383
Net cash used in operating activities	(10,618)	(20,676)	(23,139)
Cash flows from investing activities:
Purchases of property and equipment	(1,728)	(1,029)	(1,069)
Proceeds from disposal of property and equipment (Note 6)	13,242	1,007	67
Proceeds from sales of marketable securities (Note 9)	13,678	7,152	18,246
Purchase of marketable securities (Note 9)	(68,275)	(1,085)	(3,567)
Cash transferred on acquisition	0	0	1,771
Net cash provided by (used in) investing activities	(43,083)	6,044	15,448
Cash flows from financing activities:
Reimbursment of loans	(34,392)	(475)	(223)
Reimbursment of conditional grants (Note 21)	(355)	0	0
Proceeds from loans or conditional grants (Note 21)	0	19,333	6,668
Principal payments on capital lease obligations	(161)	(77)	(97)
Earn-out payment for acquisition	(1,357)	(907)	0
Cash proceeds from issuance of ordinary shares and warrants (Note 18)	132,260	400	607
Net cash provided by financing activities	95,995	18,274	6,955
Effect of exchange rate changes on cash and cash equivalents	(9,170)	252	22
Net increase (decrease) in cash and cash equivalents	33,124	3,894	(714)
Cash and cash equivalents, beginning of year	6,636	2,742	3,456
Cash and cash equivalents, end of year	39,760	6,636	2,742
Supplemental disclosures of cash flow information:
Income tax paid	403	153	56
Interest paid	4,431	1,701	118
The supplemental schedule of non cash investing and financing activities is as follows
Capital lease obligations incurred	0	0	0
Fair value of assets acquired at acquisition date:	0	0	50,927
Liabilities assumed at acquisition date:	$ 0	$ 0	$ 50,927

Nature of business and summary of significant accounting policies

12 Months Ended

Dec. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]

1.	Nature of business and summary of significant accounting policies:

1.1.

Nature of business

Flamel Technologies, S.A. (“Flamel” or the "Company") is organized as a Société Anonyme, a form of corporation under the laws of The Republic of France. The Company was founded in 1990. Flamel is a specialty pharmaceutical company with drug delivery and formulation expertise. The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and Dublin, Ireland.

1.2.

Management estimates

The accompanying consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP).

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates reflected in the consolidated financial statements include, but are not limited to, purchase price allocation of its acquisitions, remeasurement of liabilities accounted at fair value, the recoverability of the carrying amount and estimated useful lives of long-lived assets, in progress R&D and goodwill, share-based compensation expenses, evaluation of long term personnel compensation, calculation of R&D tax credit, and valuation allowance of deferred tax assets. Management makes these estimates using the best information available at the time the estimates are made; however, actual results could differ from those estimates.

1.3.

Discontinued Operations

The company divested its development and manufacturing facility in Pessac, France on December 1, 2014 to Recipharm.

The Company followed the guidance in Financial Statements Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 205 Presentation of Financial Statements (ASC 205), Topic 360 Property, Plant and Equipment (ASC 360) and Accounting Standards Update (ASU 2014-08), Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity in determining the accounting for the divestiture. The Company opted to early adopt the provisions of ASU 2014-08 as its management believes that all criteria for presenting the divestiture of the Pessac Facility and its business as a discontinued operation were met. Presenting the divestiture as a discontinued operation will also provide a better understanding of the results of the Company’s new strategy and in assessing the impact of the disposal on the ongoing operations of the entity.

The divestiture represents a strategic shift that had or will have a major effect on our operations and financial results. Since consummating the Éclat acquisition in March 2012, the Company has implemented an altered business model allowing Flamel to blend novel, high-value internally developed products with its drug delivery capabilities and to commercialize niche branded and general pharmaceutical products. Previously, the Company’s focus was to develop and license its proprietary drug delivery platforms (Micropump^®, LiquiTime^®, Trigger Lock™ and Medusa™) with pharmaceutical companies and biotechnology partners (e.g. the licensing of Micropump^® to GSK to develop Coreg CR^® with GSK commercializing the product). The divestiture of the Pessac Facility to Recipharm and the transfer to Recipharm of the GSK’s Supply Agreement and royalty income relating to Coreg CR^® is an implementation of this revised strategy. Flamel sold over 50% of its historical revenues as a result of this transaction which had or will have a major impact on the Company’s operations and financial results.

The divestiture was accomplished in a single transaction and the assets, contracts and liabilities referred to in the Asset Purchase Agreement signed between Flamel and Recipharm were determined to represent a disposal group. This disposal group is considered to be a component of the Company. While the Pessac Facility and its related business were not identified as a reportable segment or operating segment, as the Company operates in only one segment, the Pessac Facility and its related business may be considered as an asset group as the transferred assets, liabilities and contracts represent the lowest level for which identifiable cash flows are largely independent of the cash flows of any other group of assets and liabilities. Flamel transferred all future cash outflows and inflows relating to the Pessac Facility that can be clearly distinguished operationally and for financial reporting purposes.

The results of Discontinued Operations, less income taxes, have been reported as a separate component of income in the statement of operations. The assets and liabilities of the discontinued operation have been reported separately in the asset and liability sections, of the balance sheet for the periods presented therein. See note 6 to the Consolidated Financial Statements in “Item 18. Financial Statements” for a description of the facts and circumstances related to the disposal, the gain and loss on disposal and the specific line items included in the statement of operations, balance sheet and cashflow statement relative to the disposal group.

1.4.

Going concern

Management believes that the cash and cash equivalents and marketable securities of $92.8 million as of December 2014 are sufficient for the Company to continue as a going concern for at least the next twelve (12) months and does not have substantial doubt as to the organization’s ability to continue as a going concern.

1.5.

Principles of consolidation

The accompanying consolidated financial statements include the Company and its wholly-owned subsidiaries in the United States and Ireland. All inter-company accounts and transactions have been eliminated. The list of the subsidiaries is detailed in Exhibit 8.1.

1.6.

Translation of financial statements of foreign entities and foreign currency transactions

The reporting currency of the Company and its wholly-owned subsidiaries is the U.S. dollar as permitted by the SEC for a foreign private issuer (S-X Rule 3-20(a)). All financial statement amounts of the Company and any other subsidiary for which the functional currency is the Euro or any other currency other than the U.S. dollar, are translated into U.S. dollar equivalents at exchange rates as follows: (1) asset and liability accounts at year-end rates, (2) income statement accounts at weighted average exchange rates for the year, and (3) shareholders' equity accounts at historical rates. Corresponding translation gains or losses are recorded in shareholders' equity.

Transaction gains and losses are reflected in the statement of operations.

Transactions involving foreign currencies are translated into the functional currency using the exchange rate prevailing at the time of the transactions. Receivables and payables denominated in foreign currencies are translated at year-end exchange rates. The resulting unrealized exchange gains and losses are carried to the statement of operations. As of December 31, 2014 the conversion generates an unrealized exchange rate gain of approximately $11.6 million.

The Company has not undertaken hedging transactions to cover its currency translation exposure.

1.7.

Revenue recognition

Revenue includes upfront licensing fees, milestone payments for R&D achievements, compensation for the execution of R&D activities and sales of pharmaceutical products.

Where agreements have more than one deliverable, a determination is made as to whether the license and R&D elements should be recognized separately or combined into a single unit of account in accordance with ASU 2009-13, Revenue with Multiple Deliverables.

The Company uses a Multiple Attribution Model, referred to as the milestone-based method:

⋅

As milestones relate to discrete development steps (i.e. can be used by the partners to decide whether to continue the development under the agreement), the Company views that milestone events have substance and represent the achievement of defined goals worthy of the payments. Therefore, milestone payments based on performance are recognized when the performance criteria are met and there are no further performance obligations.

⋅

Non-refundable technology access fees received from collaboration agreements that require the Company's continuing involvement in the form of development efforts are recognized as revenue ratably over the development period.

⋅

R&D work is compensated at a non-refundable hourly rate for a projected number of hours. Revenue on such agreements is recognized at the hourly rate for the number of hours worked as the R&D work is performed. Costs incurred under these contracts are considered costs in the period incurred. Payments received in advance of performance are recorded as deferred revenue and recognized in revenue as services are rendered.

Revenue is generally realized or realizable and earned when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectability is reasonably assured. The Company records revenue from product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery to the customer and when the selling price is determinable. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of its products, an estimate of provision for sales return and allowances is recorded which reduces product sales. These adjustments include estimates for product returns, chargebacks, payment discounts and other sales allowances and rebates. The estimate for chargebacks is determined when product is shipped from the wholesalers to their customers. The return allowance, when estimable, is based on an analysis of the historical returns of the product or similar products.

For generic products and branded products sold in mature and stable markets where changes in selling price are rare, the Company recognizes revenues upon shipment. For branded products where market conditions remain volatile and selling price is subject to change the Company recognizes revenue based on net product sales of wholesalers to their customers. For new product launches the Company recognizes revenue once sufficient data is available to determine product acceptance in the marketplace such that product returns may be estimated based on historical data and there is evidence of reorders and consideration is made of wholesaler inventory levels. Net product sales of wholesalers to their customers are determined using sales data from an independent, renowned wholesaler inventory tracking service. Net sales of wholesalers to their customers are calculated by deducting estimates for returns for wholesaler customers, chargebacks, payment discounts and other sales or discounts offered from the applicable gross sales value. Estimates for product returns are adjusted periodically based upon historical rates of returns, inventory levels in the distribution channel and other related factors.

When Flamel receives revenue under signed feasibility study agreements, revenue is then recognized over the term of the agreement as services are performed.

The Company receives financial support for various research and investment projects from governmental agencies. Revenue from conditional grants related to specific development projects is recognized as an offset to operating expenses when all conditions stated in the grant have been met and the funding has been received. Revenues from unconditional grants for R&D projects are recognized as an offset to R&D expense on a pro-rata basis over the duration of the program. Funding can be received to finance certain R&D projects which are repayable on commercial success of the project. In the absence of commercial success, the Company is released of its obligation to repay the funds and the funds are recognized in the Income Statement as ‘Other Income’.

Flamel benefits from tax credits on a percentage of eligible R&D costs. These tax credits can be refundable in cash or offset against taxable income and are not contingent upon future taxable income. As explained in note 5 to the Consolidated Financial Statements, the company determined that the research tax credit should be classified as a R&D grant and the tax credit is recognized as an offset to R&D expense.

1.8.

Governmental Grants

The Company receives financial support for various research or investment projects from governmental agencies.

The Company recognizes conditional grants related to specific development projects conditioned on completion of investment program and ongoing employment at the facilities as an offset to operating expenses once all conditions stated in the grant have been met.

The Company recognizes unconditional grants for R&D (R&D) projects requiring the collaboration of both private and public research partners as an offset to R&D expense on a pro-rata basis over the duration of the program.

The Company receives funds to finance R&D projects. These funds are repayable on commercial success of the project. In the absence of commercial success, the Company is released of its obligation to repay the funds and as such the funds are recognized in the Income Statement as ‘Other Income’. The absence of commercial success must be formally confirmed by the granting authority. Should the Company wish to discontinue the R&D to which the funding is associated, the granting authorities must be informed.

1.9.

R&D costs

R&D expenses comprise the following types of costs incurred in performing R&D activities: salaries, allocated overhead and occupancy costs, clinical trial and related clinical or development manufacturing costs, contract and other outside service fees, filing fees and regulatory support. R&D expenditures are charged to operations as incurred.

The Company does not disclose research development costs per partner funded contract and does not believe such disclosure would be material to investors.

1.10.

Concentration of credit risk

The Company's cash and cash equivalents are mainly deposited with Morgan Stanley, Crédit Agricole, HSBC, and Commerce Bank.

The marketable securities issued by Morgan Stanley and from Crédit Agricole have strong credit ratings.

The Company’s revenues are derived mainly from product sales and services and collaborative R&D contracts with pharmaceutical companies based in Europe and the United States and wholesalers based in the United States. All significant customers are discussed in Note 3.

The Company performs ongoing credit evaluations of its customers and maintains provisions for potential credit losses as considered necessary. The Company generally does not require collateral. Historically, the Company has not experienced significant credit losses on its customer accounts. The allowance for doubtful accounts was $139,000, $144,000 and $127,000 at December 31, 2012, 2013 and 2014, respectively.

1.11.

Earnings per share

Basic earnings (loss) per share are computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted earnings per share reflects potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. The dilutive effects of the Company’s common stock options and warrants is determined using the treasury stock method to measure the number of shares that are assumed to have been repurchased using the average market price during the period, which is converted from U.S. dollars at the average exchange rate for the period. Such securities are not considered in computing diluted loss per share as their effects would be anti-dilutive.

1.12.

Cash and cash equivalents

Cash and cash equivalents consist of cash on hand, cash on deposit and fixed term deposit being highly liquid investments with a maturity of three months or less at the date of purchase.

1.13.

Marketable securities

Marketable securities consist of highly liquid investments in money market mutual funds. Marketable securities are classified as available-for-sale securities in accordance with ASC 320-10, "Accounting for Certain Investments in Debt and Equity Securities" These investments are recorded at fair value, which is based on quoted market prices. Accordingly, unrealized gains and losses are included in accumulated other comprehensive income until realized.

1.14.

Accounts Receivable

Accounts receivable are stated at amounts invoiced net of allowances for doubtful accounts. The Company makes judgments as to its ability to collect outstanding receivables and provides allowances for the portion of receivables deemed uncollectible. Provision is made based upon a specific review of all significant outstanding invoices.

1.15.

Inventories

Inventories consist of raw materials and finished products, which are stated at cost determined under the first-in, first-out ("FIFO") method. Raw materials used in the production of pre-clinical and clinical products are expensed as R&D costs when consumed. The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow-moving on a case by case basis.

1.16.

Property and equipment

Property and equipment is stated at historical cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:

Land and buildings		20 years
Laboratory equipment		4 - 8 years
Office and computer equipment		3 years
Furniture, fixtures and fittings		5-10 years

1.17.

Goodwill and intangible assets

Goodwill represents the excess of purchase price over the fair value of identifiable net assets of businesses acquired. Goodwill is not amortized, but instead tested annually for impairment or more frequently when events or change in circumstances indicate that the assets might be impaired by comparing the carrying value to the fair value of the reporting units to which it is assigned. Under ASC 350, “Goodwill and other intangible assets”, the impairment test is performed in two steps. The first step compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit is less than its carrying amount, a second step is performed to measure the amount of impairment loss. The second step allocates the fair value of the reporting unit to the Company’s tangible and intangible assets and liabilities. This derives an implied fair value for the reporting unit’s goodwill. If the carrying amount of the reporting units goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized equal to that excess. For the purpose of any impairment test, the Company relies upon projections of future undiscounted cash flows and takes into account assumptions regarding the evolution of the market and its ability to successfully develop and commercialize its products.

Changes in market conditions could have a major impact on the valuation of these assets and could result in additional impairment losses.

Intangible assets consist primarily of purchased licenses and intangible assets corresponding to acquired, in progress R&D recognized as part of the Éclat acquisition purchase price allocation. Acquired IPR&D has an indefinite life and is not amortized until completion and development of the project, at which time the IPR&D becomes an amortizable asset. Amortization of acquired IPR&D is computed using the straight-line method over estimated useful life of the assets.

1.18.

Impairment of Long-Lived Assets

The Company reviews the carrying value of its long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be fully recoverable. Recoverability of long-lived assets is assessed by a comparison of the carrying amount of the asset (or the group of assets, including the asset in question, that represents the lowest level of separately-identifiable cash flows) to the total estimated undiscounted future cash flows expected to be generated by the asset or group of assets. If the future net undiscounted cash flows is less than the carrying amount of the asset or group of assets, the asset or group of assets is considered impaired and an expense is recognized equal to the amount required to reduce the carrying amount of the asset or group of assets to its then fair value. Fair value is determined by discounting the cash flows expected to be generated by the asset, when the quoted market prices are not available for the long-lived assets. Estimated future cash flows are based on management assumptions and are subject to risk and uncertainty.

1.19.

Income taxes

The Company accounts for income taxes in accordance with ASC 740. Under ASC 740, deferred tax assets are determined based on the difference between the financial reporting and tax basis of assets and liabilities, applying enacted statutory tax rates in effect for the year in which the tax differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in the tax laws and rates on the date of enactment.

1.20.

Research credit tax

The Company is eligible to receive a French research tax credit that is calculated based on a percentage of eligible R&D costs. The tax credit can be refundable in cash and is not contingent on future taxable income. As such, the Company considers the research credit tax as a grant, offsetting operating expenses.

1.21.

Employee stock options and warrants

The Company accounts for Stock based compensation based on grant-date fair value estimated in accordance with ASC 718.

The Company estimated the fair value of stock options and warrants using a Black-Scholes option-pricing valuation model (“Black-Scholes model”).

The Company uses a simplified method to estimate the maturity. The Company considered historical data was insufficient and irrelevant relative to the grant of stock-options and warrants to a limited population and the simplified method was used to determine the expected term for stock-options and warrants granted.

The Company recognizes compensation cost, net of an estimated forfeiture rate, using the accelerated method over the requisite service period of the award.

1.22.

Long-Term Debt

The Long Term debt associated with the acquisition liabilities arising from the acquisition of Eclat Pharmaceuticals are accounted at fair-value (see note 2 –Business Combinations and note 16 Long-Term Debt). Changes in fair value are recorded in the income statement in operating expenses as remeasurement of acquisition liabilities.

The long-term debt associated with the Deerfied Facility and Broadfin Facility Agreements are accounted for at amortized cost and were fully reimbursed in March 2014. The Company elected the fair value option for the measurement of the long-term liability associated with the Deerfield and Broadfin Royalty Agreements (see note 16 Long-Term Debt). Changes in fair value are recorded in the income statement in interest expense on the debt related to the royalty agreement.

1.23.

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from contracts with customers (topic 606)” (“ASU 2014-09”). ASU 2014-09 is effective for reporting periods beginning after December 15, 2016. The Company is assessing the impact of the provisions of ASU 2014-09 on the consolidated financial position and results of operations of the Company.

In April 2014, the FASB issued ASU No. 2014-08, “Presentation of Financial Statements (topic 205) and Property, Plant, and Equipment (Topic 360)” (“ASU 2014-08”). ASU 2014-08 requires new disclosures related to Discontinued Operations. ASU 2014-08 is effective for reporting periods beginning after December 15, 2014. The company has elected to adopt ASU No. 2014-08 as of December 31, 2014. See 1.3 and note 6 – Discontinued Operations.

In August 2014, the FASB issued ASU Update No. 2014-15, Presentation of Financial Statements – Going Concern: Disclosure of Uncertainties about an Entity’s Ability to continue as a Going Concern (subtopic 205-40). Update 2014-15 requires management to assess an entity’s ability to continue as a going concern every reporting period, and provide certain disclosures if management has substantial doubt about the entity’s ability to operate as a going concern, or an express statement if not, by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Update 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. Upon adoption the Company will use the guidance in ASU 2014-15 to assess going concern. Management believes that the cash and cash equivalents of $92.8 million as of December 2014 are sufficient for the company to continue as a going concern for at least the next twelve months and does not have substantial doubt as to the organization’s ability to continue as a going concern.

Business combinations

12 Months Ended

Dec. 31, 2014

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

2.	Business combinations

Effective March 13, 2012, Flamel acquired, through its wholly owned subsidiary Flamel US Holdings, Inc., or Flamel US, all of the membership interests of Éclat Pharmaceuticals, LLC (or “Éclat Pharmaceuticals”) from Éclat Holdings, LLC (or “Éclat Holdings”) an affiliate of Flamel’s largest shareholder Deerfield Capital L.P. Éclat Pharmaceuticals operates as a specialty pharmaceuticals business focused on the development, approval and commercialization of niche brands and generic pharmaceutical products. In exchange for all of the issued and outstanding membership interests of Éclat Pharmaceuticals, Flamel US provided consideration consisting of:

a $12 million senior, secured six-year note that is guaranteed by the Company and its subsidiaries and secured by the equity interests and assets of Éclat;

two warrants to purchase a total of 3,300,000 American Depositary Shares, each representing one ordinary share of Flamel (“ADSs”)

a commitment to make earn out payments of 20% of any gross profit generated by certain Éclat Pharmaceuticals products

a commitment to pay 100% of any gross profit generated by Hycet^® up to a maximum of $1 million.

The Purchase Agreement also contains certain representations and warranties, covenants, indemnification and other customary provisions.

The $12 million senior secured six-year note that accrued interest at an annual rate of 7.5% was repaid on March 24, 2014 (see note 16 – Long Term Debt).

In addition to the note, two six year warrants were issued to purchase an aggregate of 3,300,000 ADSs, each representing one ordinary share, of Flamel. One warrant is exercisable for 2,200,000 ADSs at an exercise price of $7.44 per ADS, and the other warrant is exercisable for 1,100,000 ADSs at an exercise price of $11.00 per ADS.

The acquisition-date fair value of the consideration transferred totaled $50,927,000 which consisted of the following:

(Amounts in thousands of US dollars)
Note		5,625
Warrants		12,065
Deferred consideration		33,237
Total acquisition liabilities		50,927

The fair value of the note was estimated using a probability-weighted discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a level 3 measurement as defined in ASC 820. The key assumptions are as follows: 20% discount rate, 72% probability of success.

The fair value of the warrants was determined by using a Black-Scholes option pricing model with the following assumptions:

Share price	$	7.29
Risk-free interest rate		2.00	%
Dividend yield		-
Expected volatility		56.26	%
Expected term		6.0 years

The deferred consideration fair value was estimated by using a discounted cash flow model based on probability adjusted annual gross profit of each of the Éclat Pharmaceuticals products. A discount rate of 20% has been used, except for Hycet^® for which a discount rate of 13% has been retained.

The Company’s result of operations in future periods will be affected by the movements in the fair value of the acquisition liabilities which are remeasured at each balance sheet date. Changes in fair value will be recognized in operating income. Changes in assumptions or other variants used to calculate the fair value of acquisition liabilities, such as, but not limited to, the Company’s share price, volatility of the share price, discount rates, probability assessment of success in completing development and commercializing acquired products, market share, market size and selling prices negotiated for each product will have an effect on the fair value of the acquisition liabilities. (See note 16 Long Term Debt and note 21 Fair Value of Financial Instruments).

The transaction was accounted for as a business combination under the acquisition method of accounting. Accordingly, the tangible assets and identifiable intangible assets acquired and liabilities assumed were recorded at fair value, with the remaining purchase price recorded as goodwill.

A total of $47.3 million of the acquired intangible assets was allocated to in-process R&D (IPR&D) assets that were recognized at fair value on the acquisition date. The fair value was determined using an income approach, including a discount rate of 20%, applied to probability adjusted after-tax cash flows. The estimated costs to complete the IPR&D projects represents management’s best estimate of expected costs. The difference between the purchase price and the fair value of the assets acquired and liabilities assumed of $18.5 million was allocated to goodwill. This goodwill is attributable to the remaining product opportunities identified by the acquired entity at the date of acquisition, but for which limited development had occurred and the regulatory approval process had not commenced. None of the goodwill is expected to be deductible for income tax purposes.

(See note 13 Goodwill and Intangible Assets).

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

License, research and consulting agreements

12 Months Ended

Dec. 31, 2014

License, Research and Consulting Agreements [Abstract]

License, Research and Consulting Agreements Disclosure [Text Block]

License, research and consulting agreements:

3.1.

Merck Serono, a division of Merck KGaA

On December 20, 2007 Flamel Technologies entered into a relationship with Merck Serono, a division of Merck KGaA, to investigate the applicability of Flamel’s Medusa™ for the extended release of a therapeutic protein of Merck Serono’s portfolio.

In consideration of the agreement signed in 2007, Merck Serono made an upfront payment of $2.7 million, which has been amortized over the initial feasibility period. In February 2009 Merck Serono exercised the option to license Medusa™ triggering a payment of $ 6.5 million (€5.0 million). Under the terms of the agreement, the Company was eligible to receive up to $53.0 million (€41.0 million) in milestone payments upon certain agreed-upon development events.

On November 2, 2012, Flamel received notice from Merck Serono to terminate for convenience the development and license agreement, effective January 31, 2013. For the year 2012, the Company recognized $2,745,000 of amortization of the initial up-front and option payments, of which $1,426,000 relates to accelerated amortization due to termination.

3.2.

Eagle Pharmaceuticals

On October 12, 2011 the Company entered into a license and development agreement with Eagle Pharmaceuticals for the development of a Medusa™-based hydrogel depot formulation of the small molecule antibiotic, tigecycline. In consideration of this agreement, the Company recognized R&D revenues of $345,000. Milestone payments amounting to $1.2 million (€0.9 million) will be received upon achievement of certain development and commercial events.

In 2012, the Company recognized R&D revenues of $659,000. The Company also recognized $43,000 of amortization of the initial up-front fee.

In 2013, the Company recognized R&D revenues of $31,600 as amortization of the initial up-front fee

3.3.

Corning

In December 1998, the Company signed a long-term research and product development agreement with Corning France and Corning Incorporated. Pursuant to the terms of this agreement, Flamel received royalties on the sales of Corning products that utilize Flamel’s innovations.

The Company recognized royalties on Corning’s sales of $152,000 in 2012, $111,000 in 2013 and on February 12, 2014 the Company signed an amendment effectively terminating the research and product development agreement and received a payment of $336,000 excluding sales taxes.

3.4.

Others

The Company recognized license and R&D revenues with undisclosed partners for an amount of $3.3 million in 2012; $3.0 million in 2013 and $2.8 million in 2014.

Product sales and services

12 Months Ended

Dec. 31, 2014

Product sales and services [Abstract]

Product sales and services [Text Block]

4.	Product sales and services

Flamel recognized product sales of $11.9 million in 2014 compared to $1.0 million in 2013 and $0.6 million in 2012.

The Company launched Bloxiverz^® in July of 2013 and determined that market acceptance of the product had not occurred given the absence of wholesaler reorders and insufficient data to determine product returns. For the twelve months ended December 31, 2013, the criteria for recognizing the revenue were not met and the Company deferred $1.1M of revenue as of December 31, 2013. The Company determined as of March 31, 2014 that given significant wholesaler reorders and sufficient data obtained from the independent wholesaler tracking service regarding product returns from its customers, the Company could begin recognizing net product sales of Bloxiverz^® based on indirect sales. Net product sales of wholesalers to their customers are determined using sales data from an independent, wholesaler inventory tracking service and are calculated by deducting estimates for returns for wholesalers’ customers, chargebacks, payment discounts and other sales or discounts offered from the applicable gross sales value. Bloxiverz^® product is purchased by hospitals from the wholesalers primarily through contractual agreements with group purchasing organizations (“GPOs”). The Company recognized net product sales of $10.2 million in the twelve months ended December 31, 2014 for Bloxiverz^® sales from wholesalers to hospitals. A total of $7.0M of net revenue on shipments to wholesalers has been deferred as of December 31, 2014. Gross product sales to hospitals amounted to $15.8 million in the twelve months ended December 31, 2014.

The Company launched Vazculep™ in October of 2014 and determined that market acceptance of the product had not occurred given its short period of time on the market and that sufficient data to determine product returns had not yet been achieved. For the twelve months ended December 31, 2014, the criteria for recognizing the revenue were not met and the Company deferred $2.7 million of revenue as of December 31, 2014.

A summary of recognized net sales for the twelve months ended December 31, 2014 and ending net deferred sales as of December 31, 2014 for the Company’s two (2) FDA-approved products as of December 31, 2014 is presented below:

Year Ended December 31, 2014 ($ in thousands)	Sales Recognized in the Current Period		Deferred Sales		Deferred Sales reclassed against outstanding Accounts Receivable		Ending Deferred Sales for which Payment has been Collected
Gross Sales	$	15,789	$	11,051	$	(9,420)	$	1,630
Less:
Chargebacks	$	3,363	$	132	$	(23)	$	109
Wholesaler distribution fees		1,470		972		(823)		149
Cash discounts and other		326		225		(188)		37
Fees and returns		419		-		-		-
Net Sales	$	10,211	$	9,722	$	(8,386)	$	1,335

The sales deductions discussed above are presented in the consolidated financial statements as reductions to gross revenues or deferred revenue, as presented above, and a decrease to accounts receivable or an increase to accrued liabilities. A summary of fiscal year 2014 changes for each reserve or liability for Bloxiverz^®, Vazculep™ and the Company’s generic pharmaceutical product is as follows:

Year Ended December 31, 2014 ($ in Thousands)	Beginning Balance		Additions		Reductions		Ending Balance
Accounts Receivable Reserves:
Chargebacks	$	483	$	4,832	$	(4,307)	$	1,008
Wholesaler distribution fees		102		2,619		(1,642)		1,079
Cash Discounts and other		28		733		(508)		252

Liabilities:
GPO fees	$	6	$	267	$	(161)	$	112
Sales returns		42		200		(8)		234
Medicaid rebates		37		16		(29)		24
Total		698		8,667		(6,656)		2,709

Actual product returns and other allowances incurred are dependent upon future events and may be different from the Company’s recorded provisions. The Company continually monitors the factors that influence such estimates and makes adjustments when it is believed that deductions may differ from established allowances.

R&D expenses

12 Months Ended

Dec. 31, 2014

Research and Development Expenses [Abstract]

Research and Development Expenses [Text Block]

5.	R&D expenses

Total R&D expenditures can be disaggregated in the following significant type of expenses ($USD in millions):

In millions of U.S. Dollars	2012		2013		2014
R&D Expenses		21.2		21.8		22.8
R&D Tax Credit		(6.5)		(5.8)		(5.5)
Grants		(0.1)		-		-
Total		14.6		16.0		17.3

As of December 31, 2012 the Company recognized to the income statement unconditional grants for a total of $103,000. No unconditional grants have been recognized to the income statement in 2013 and 2014.

Discontinued Operations

12 Months Ended

Dec. 31, 2014

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

6.	Discontinued Operations

On December 1, 2014, the Company signed an Asset Purchase Agreement with Recipharm for the divestiture of its development and manufacturing facility located in Pessac, France.

The assets included in the divestiture were tangible equipment, furniture and fixtures, inventories and all intellectual property rights relating to the operation and technological know-how necessary in manufacturing the products that are produced in the facility and the assignment to Recipharm of all employees, customer contracts and liabilities which primarily relate to agreements of the Company with GlaxoSmithKline (“GSK”) for the manufacture and sale of Coreg CR^®. Coreg CR^® was Flamel’s lead product using the Micropump drug delivery platform that was developed with GSK and has been approved and sold in the US since 2007. The semi-finished product is manufactured in the Pessac Facility. The contracts assigned to Recipharm exclude the Amended 2003 License Agreement and 2004 License Agreement (collectively “License Agreements”) between Flamel and GSK for the development of Coreg CR^®. However, the royalties to be earned by Flamel from the sales of Coreg CR^® were transferred to Recipharm as part of the Asset Purchase Agreement. All costs and future revenues relating to the manufacture and sale of Coreg CR^® were transferred to Recipharm.

Royalties from Coreg CR^® sales amounted to $6.9 million in 2012, $6.8 in 2013 and $6.3 in 2014. Revenues from sales of Coreg CR^® microparticles to GSK amounted to $9.1 in 2012, $8.0 million in 2013 and $6.7 million for 2014. Revenues from research revenues with undisclosed partners amounted to $2.6 million in 2012, $3.5 million in 2013 and $2.0 million in 2014.

The supply Agreement originally signed between Flamel and GSK in December 2004, included payments to Flamel of $20,717,000 to support the costs and capital expenditure relative to the creation of a manufacturing area for the production of commercial supply of the product. The capital expenditures consist of both buildings and fixtures, and production equipment with Flamel having immediate title to buildings and fixtures. However, title to production equipment remains with GSK for the duration of the supply agreement. A total of $8,188,000 was incurred on the acquisition of buildings and fixtures and a total of $11,138,000 was incurred on behalf of GSK for the purchase of production equipment and associated costs.

In July 2006, Flamel and GSK entered into a further agreement whereby GSK partly sponsored the extension of the then existing Pessac Facility from two lines to three. GSK had exclusive use of part of this equipment for the production of Coreg CR^® microparticles. The total funding provided by GSK amounted to $8.1 million to finance the acquisition of equipment, buildings and fixtures.

The funds received from GSK to finance the acquisition of assets owned by Flamel were classified as other liabilities (current and long-term) and amortized on a pro-rata basis over the expected life of the related assets and as an offset of the depreciation of the related assets. On the divestiture of the facility the remaining liability was offset against the gain on sale of the tangible assets.

The aggregate consideration paid for the acquired assets and business was $13.2 million, plus the value of acquired inventory determined using inventory valuation methodology as defined by the two parties. All cash and receivables pertaining to Pessac Facility business prior to the sale were retained by Flamel. A contribution of $0.7 million was made to finance potential future retirement indemnities payable on transferred employees. The business was accounted for as a discontinued operation in the fourth quarter of 2014 and, therefore, the operating results of our Pessac Facility business were included in Discontinued Operations in our consolidated financial statements for all years presented. We recognized a $5.0 million gain on disposal, which was included in our income from Discontinued Operations, in fiscal year 2014.

Summary results of operations for the Pessac business were as follows:

	Fiscal Year
In thousands of U.S. Dollars	2012		2013		2014

Revenues	$	18,570	$	18,265	$	14,967
Income (loss) from operations		1,550		3,667		(875)
Gain (loss) on disposal		-		-		5,007
Interest Expense		(11)		(9)		(4)
Income taxes		(27)		(74)		(110)
Income (loss) from discontinued operations, net of tax	$	1,512	$	3,584	$	4,018

Carrying amounts of major classes of assets and liabilities classified as held for sale in the statement of financial position are as follows:

	December 31,
In thousands of U.S. Dollars	2013		2014

Accounts receivable, net	$	-	$	730
Inventories		1,352		-

Total major classes of current assets of the discontinued operations		1,352		730

Net Property, plant and equipment		15,044		-
Total major classes of non current assets of the discontinued operations		15,044		-
Total assets of the disposal group classified as held for sale		16,396		730

Current portion of capital lease obligations		69
Accounts payable		-		168
Other current liabilities		832		-
Total major classes of Current Liabilities of the discontinued operations		901		168

Capital lease obligations, less current portion		88		-
Other liabilities		7,626		-
Total major classes of Non-Current Liabilities of assets Held for sale		7,714		-
Total liabilities of the disposal group classified as held for sale		8,615		168

The major cash-flows related to Discontinued Operations presented in the statement of cash-flows are as follows

	2012		2013		2014
Capital Expenditures	$	766	$	872	$	1,271
Depreciation and Amortization		1,910		1,751		1,709
Operating and Investing non-cash elements		(975)		(676)		(740)

In connection with the Asset Purchase Agreement, the Company entered into a number of other agreements with Recipharm.

Master Agreement on Supply and Services of Products (“MSA”)

Recipharm will provide various services in the domain of R&D and manufacture of pharmaceutical products for an initial non-cancellable period of five years.

Over the initial term, any services to be provided to shall include internal and external costs incurred by Recipharm plus 20%, which has been determined to be fair value for such services. The minimum amount of services per year, for a cumulative total of $22.5 million as follows:

First Year	$	4.25 millions
Second Year	$	4.25 millions
Third Year	$	4.25 millions
Fourth and Fifth Year each	$	4.86 millions

Transitional Service Agreement

In order to provide for the orderly transition of the Pessac Facility business to Recipharm, transitional services will be provided over a period of six months. The Transition services include primarily back office support such as information technology, human resources, accounting and other services as defined in the Transition Services Agreement.

Option Agreement

Recipharm has a first option (right of first refusal) to discuss and negotiate licenses of Flamel’s intellectual property rights for the sale certain products in Europe. Upon exercise of the option, Recipharm and Flamel shall agree in good faith on terms and conditions of related license agreement within forty-five (45) days from the exercise of the option. The term of the Option Agreement is from the signing of the agreement through December 31, 2017. Flamel received no compensation related to the option agreement.

Concurrently with the above, Recipharm made an investment of $13.0 million in newly issued Flamel shares which corresponds to approximately 2.3% of Flamel’s shareholdings. The purchase price for the shares purchased by Recipharm was based on the average of the trailing 20 days’ trading prices of Flamel’s shares prior to the closing date.

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

+ Details

Stock based compensation

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

7.	Stock based compensation

7.1.

ASC 718

The Company applies the provisions of ASC 718 in accounting for its stock based compensation. The fair value of each option and warrant granted during the year is estimated on the date of grant using the Black-Scholes option pricing model. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The weighted-average assumptions on grants made in each of the following years were:

	Year Ended December 31
	2012			2013			2014
Weighted-average expected life (years)	$	5.70		$	5.43		$	4.26
Expected volatility rate		62.50	%		61.00	%		61.00	%
Expected dividend yield		-			-			-
Risk-free interest rate		0.95	%		1.40	%		1.23	%
Forfeiture rate		-			-			-

We base our determination of expected volatility predominantly on the implied volatility of our traded options with consideration of our historical volatilities. Given the limited historical data and the grant of stock options and warrants to a limited population, the simplified method has been used to calculate the expected life.

Stock based compensation expense recognized was as follows:

As of December 31, 2013, the projected compensation expense related to non-vested options or warrants amounted to $4,090,000 and are expected to be recognized over a weighted average period of 2.13 years.

As of December 31, 2014, the projected compensation expense related to non-vested options or warrants amounted to $10,899,000 and are expected to be recognized over a weighted average period of 2.15 years.

(In thousands of U.S dollars except per share data)	Options						Free of charge share awards						Warrants						Total
	2012		2013		2014		2012		2013		2014		2012		2013		2014		2012		2013		2014
Research and development		419		398		327		649		320		494		-		61		206		1,068		779		1,027
Cost of goods sold		2		1		1		46		19		38		-		-		-		49		20		38
Selling, general and administrative		1,280		903		765		464		211		390		179		116		643		1,923		1,230		1,798

Total stock-based compensation expense		1,701		1,302		1,093		1,160		550		921		179		177		850		3,040		2,029		2,863

Effect on earnings per share
Basic		0.07		0.05		0.03		0.05		0.02		0.03		0.01		0.01		0.02		0.12		0.08		0.08

Diluted		0.07		0.05		0.03		0.05		0.02		0.03		0.01		0.01		0.02		0.12		0.08		0.08

7.2.

Warrants

The summary of warrants activity is as follows:

	Warrants Outstanding		Weighted Average Exercise Price in U.S dollars [1]		Weighted Average Exercise Price in Euros
Balance at January 1, 2012		900,000	$	6.89	€	4.85
Warrants granted		3,300,000	$	8.63	€	6.61
Warrants reintegrated		100,000	$	6.65	€	4.97
Warrants cancelled		200,000	$	10.20	€	6.57
Balance at December 31, 2012		4,100,000	$	8.12	€	6.18
Warrants granted		200,000	$	6.14	€	4.58
Warrants exercised		50,000	$	6.29	€	4.50
Warrants cancelled		200,000	$	6.29	€	4.50
Balance at December 31, 2013		4,050,000	$	8.14	€	6.21
Warrants granted		298,000	$	14.54	€	10.94
Warrants exercised		445,000	$	6.12	€	4.49
Warrants cancelled		50,000	$	7.02	€	5.44
Balance at December 31, 2014		3,853,000	$	8.86	€	6.76

[1] Historical exchange rate at date of grant

445,000 warrants were exercised in 2014, 50,000 warrants were exercised in 2013 and no warrants were exercised in 2012.

Exercise prices and intrinsic value for warrants outstanding as of December 31, 2014 were as follows:

	Warrants Outstanding								Warrants Exercisable
Range of exercise prices in euros	Number of shares		Weighted average remaining contractual life		Weighted average exercise price in euros		Weighted average intrinsic value in euros		Number of shares		Weighted average exercise price in euros		Weighted average intrinsic value in euros

0 to 4.58		255,000		1.69		4.17		9.94		255,000		4.17		9.94
5.44 to 6.57		2,200,000		3.20		5.70		8.41		2,200,000		5.70		8.41
6.58 to 8.52		1,100,000		3.20		8.42		5.69		1,100,000		8.42		5.69
8.52 to 10.94		298,000		3.62		10.94		3.17
		3,853,000		3.13		6.78		7.33		3,600,000		6.43		7.68

The total fair value of warrants vested during 2012 amounted to €271,000 or $348,000 (average exchange rate of the year).

No warrants were vested during 2013.

The total fair value of warrants vested during 2014 amounted to €225,500 or $300,000 (average exchange rate of the year).

Intrinsic value represents the variance between the share price and the exercise price. As of December 31, 2014 the aggregate intrinsic value of warrants outstanding amounted to €28,237,000 or $37,070,000 (historical exchange rate at date of grant).

7.3.

Stock Options

The activity under the option plans is as follows:

	Shares Available for Grant			Options Granted and Outstanding			Weighted Average Exercise Price in U.S dollars[1]		Weighted Average Exercise Price in Euros
Balance at January 1, 2012		275,000			3,140,990		$	14.65	€	11.66
Options authorized		1,000,000			-			-		-
Granted		(550,000	)		550,000		$	5.97	€	4.67
Exercised		-			(195,000	)	$	2.04	€	2.33
Forfeited		10,000			(223,500	)	$	16.88	€	13.69
Balance at December 31, 2012		735,000			3,272,490		$	13.79	€	10.90
Options authorized		600,000			-			-		-
cancelled		(10,000	)		-			-		-
Granted		(710,000	)		710,000		$	5.97	€	4.36
Forfeited		13,000			(647,500	)	$	15.29	€	12.63
Balance at December 31, 2013		628,000			3,334,990		$	11.84	€	9.17
Options authorized		1,700,000			-			-		-
cancelled		(628,000	)		-			-		-
Granted		(669,500	)		669,500		$	16.30	€	13.15
Exercised		-			(550,750	)	$	6.28	€	4.57
Forfeited		-			(955,500	)	$	19.19	€	15.00
Balance at December 31, 2014		1,030,500			2,498,240		$	11.45	€	9.02

[1] Historical exchange rate at date of grant

The total intrinsic value of options exercised during 2012 amounted to €735,000 or $973,000 (historical exchange rate at date of exercise).

No options were exercised during 2013.

The total intrinsic value of options exercised during 2014 amounted to €2,864,000 or $3,789,000 (historical exchange rate at date of exercise).

Stock options outstanding at December 31, 2014, which expire from 2015 to 2024, had exercise prices ranging from €3.00 to € 25.39. The weighted average remaining contractual life of all options is 7 years. As of December 31, 2014, there were 2,498,440 outstanding options at a weighted average exercise price of €9.02, of which 1,266,990 were exercisable at a weighted average price of €8.90. Exercise prices and intrinsic value for options outstanding as of December 31, 2014 were as follows:

	Stock Options Outstanding								Stock Options Exercisable
Range of exercise prices in euros	Number of shares		Weighted average remaining contractual life		Weighted average exercise price in euros		Weighted average intrinsic value in euros		Number of shares		Weighted average exercise price in euros		Weighted average intrinsic value in euros

0 to 3.28		284,750		7.98		3.02		11.09		84,500		3.06		11.05
4.03 to 5.44		1,069,250		7.72		4.96		9.15		707,750		4.89		9.22
6.40 to 12.02		62,000		0.19		11.42		2.69		62,000		11.42		2.69
12.86 to 16.56		970,990		7.09		13.49		0.88		301,490		14.25		1.19
19.2 to 25.39		111,250		1.59		22.98		-		111,250		22.98		-

		2,498,240		7.05		9.02		8.34		1,266,990		8.90		7.57

The total fair value of options vested during 2012 amounted to €846,000 or $1,088,000 (average exchange rate of the year).

The total fair value of options vested during 2013 amounted to €999,000 or $1,327,000 (average exchange rate of the year).

The total fair value of options vested during 2014 amounted to €952,000 or $1,265,000 (average exchange rate of the year).

The aggregate intrinsic value of options outstanding amounted to €13,964,000 or $18,555,000 (historical exchange rate at date of grant). The aggregate intrinsic value of options exercisable amounted to €7,981,000 or $10,606,000 (historical exchange rate at date of grant).

7.4.

Free share awards

The activity under the free share award plans is as follows:

	Free of Charge Share Award Available for Grant			Free of Charge Share Award Granted and Outstanding			Weighted Average Fair Value at grant date in U.S dollars[1]		Weighted Average Fair Value at grant date in Euros
Balance at January 1, 2012		26,600			440,650		$	5.81	€	4.36
Options authorized		200,000			-			-		-
Granted		(189,700	)		189,700		$	3.07	€	2.38
Exercised		-			(258,150	)	$	6.52	€	4.92
Forfeited		21,550			(21,550	)	$	5.79	€	4.35
Balance at December 31, 2012		58,450			350,650		$	3.81	€	2.88
Options authorized		200,000			-			-		-
Granted		(192,500	)		192,500		$	7.36	€	5.35
Exercised		-			(137,150	)	$	4.39	€	3.28
Forfeited		20,600			(38,400	)	$	5.10	€	3.72
Balance at December 31, 2013		86,550			367,600		$	5.32	€	3.93
Options authorized		250,000			-			-		-
Granted		(188,300	)		188,300		$	16.30	€	13.15
Exercised		-			(150,600	)	$	3.07	€	2.38
Forfeited		0			(3,750	)	$	7.36	€	5.35
Cancelled		(86,550	)
Balance at December 31, 2014		61,700			401,550		$	11.29	€	8.82

[1] Historical exchange rate at date of grant

As of December 31, 2012 the total fair value (or intrinsic value) of Free Share Awards outstanding amounted to €1,009,000 or $1,336,000 (historical exchange rate at date of grant).

As of December 31, 2013 the total fair value (or intrinsic value) of Free Share Awards outstanding amounted to €1,446,000 or $1,954,000 (historical exchange rate at date of grant).

As of December 31, 2014 the total fair value (or intrinsic value) of Free Share Awards outstanding amounted to €3,544,000 or $4,533,000 (historical exchange rate at date of grant).

Cash and Cash Equivalents

12 Months Ended

Dec. 31, 2014

Cash and Cash Equivalents [Abstract]

Cash and Cash Equivalents Disclosure [Text Block]

8.	Cash and Cash Equivalents

Cash consists of cash on deposit and fixed term investments held in several major banks and cash on hand. The components of cash and cash equivalents were as follows:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Morgan Stanley	$	0	$	7,784
HSBC		3,657		16,480
Credit Agricole		48		13,529
Commerce Bank		2,898		1,916
Other		33		51
Total cash and cash equivalents	$	6,636	$	39,760

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References + Details

Marketable securities

12 Months Ended

Dec. 31, 2014

Investments, Debt and Equity Securities [Abstract]

Cash Cash Equivalents And Marketable Securities [Text Block]

9.	Marketable securities

Marketable securities are classified as available-for-sale securities and are recorded at fair market value. Unrealized gains and losses are recorded as other comprehensive income in shareholder’s equity, net of income tax effects.

As of December 31, 2012, 2013 and 2014 marketable securities amounted respectively to $6.4 million, $0.4 million and $53.1 million.

As of December 31, 2012, 2013 there were no unrealized gains or losses. As of December 31, 2014, an unrealized loss of $0.2 million has been recognized.

(in thousands of U.S dollars)	Fair value						Value at cost						Unrealized Gains (Losses)
	2012		2013		2014		2012		2013		2014		2012		2013		2014
Credit Agricole securities		6,413		401		12,494		6,413		401		12,494		-		-		-
Morgan Stanley securities				-		40,580				-		40,382				-		(198)
Total		6,413		401		53,074		6,413		401		52,876		-		-		(198)

Gross realized gains on sales of these available-for-sale securities amounted to $6,000, $0 and $963,000 for the years ended December 31, 2012, 2013 and 2014, respectively.

(in thousands of U.S dollars)	Proceeds from sales						Purchase of securities						Gross gains						Gross Losses
	2012		2013		2014		2012		2013		2014		2012		2013		2014		2012		2013		2014
Credit Agricole securities		15,030		7,152		13,678		3,573		1,085		27,752		3		-		243		-		-		-
Morgan Stanley securities				-		-				-		40,523						720		-		-		(416)
HSBC securities		3,216		-		-		-		-		-		3		-		-		-		-		-
Total		18,246		7,152		13,678		3,573		1,085		68,275		6		-		963		-		-		(416)

Inventory

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

10.

Inventory

The components of inventories were as follows:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Raw materials		918		1,661
Finished goods		1,492		5,068

Inventories, net		2,410		6,729

Prepaid expenses and other current assets

12 Months Ended

Dec. 31, 2014

Prepaid Expenses and Other Current Assets [Abstract]

Prepaid Expenses And Other Current Assets Disclosure [Text Block]

11.	Prepaid expenses and other current assets

The components of prepaid expenses and other current assets were as follows:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Valued-added tax recoverable		689		1,077
Prepaid expenses		1,478		3,225
Advance to suppliers		219		111
Others current assets		95		5
Total Prepaid expenses and other current assets		2,481		4,418

The increase in prepaid expenses relates to deferred income tax expense, see note 19 – Income taxes.

Property and Equipment

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

12.	Property and Equipment

The components of property and equipment were as follows:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Land and buildings		-		-
Laboratory equipment		10,985		9,801
Office and computer equipment		3,423		3,289
Furniture, fixtures and fittings		5,067		4,544
Construction in progress		-		-
Total property and equipment		19,475		17,633
Less accumulated depreciation and amortization		(17,084)		(15,857)
Property and equipment, net		2,391		1,776

Depreciation expense related to property and equipment amounted to $0.8 million, $0.8 million and $0.7 million for the years ended December 31, 2012, 2013 and 2014, respectively.

Goodwill and intangible assets

12 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

13.	Goodwill and intangible assets

	December 31,
	2013								2014
(In thousands of U.S. dollars)	Gross carrying amount		Accumulated amortization		Impairment		Intangible assets, net		Gross carrying amount		Accumulated amortization		Impairment		Intangible assets, net
Goodwill	$	544		(544)		-		-	$	-		-		-		-
Goodwill Eclat acquisition		18,491		-		-		18,491		18,491		-		-		18,491
Total Goodwill	$	19,035	$	(544)	$	-	$	18,491	$	18,491	$	-	$	-	$	18,491
Intangible asset corresponding to acquired IPR&D of Bloxiverz		35,248		-				35,248		35,248		(11,749)				23,499
Intangible asset corresponding to acquired IPR&D of Vazculep		12,061				(7,170)		4,891		12,061				(7,170)		4,890
Total Intangible assets	$	47,309	$	-	$	(7,170)	$	40,139	$	47,309	$	(11,749)	$	(7,170)	$	28,389

Intangible assets corresponding to acquired in-process R&D of Bloxiverz® is being amortized straight-line over a 3 year period as of January 1, 2014. Intangible assets corresponding to acquired in-process R&D of Vazculep™ will be amortized straight-line over a 6-year period as of January 1, 2015.

The Company conducts impairment tests of intangible assets and recognized an expense of $7,170,000 in the year ended December 31, 2012, based on the management’s best estimates of the present value of future cash flows compiled on a project by project and product by product basis. The impairment of these assets resulted from new facts and circumstances that occurred regarding the potential competitive landscape of Vazculep™ at that time.

Total future amortization of intangible assets related to Bloxiverz® and Vazculep™ for the next five years ending December 31 are as follows:

(In thousands of U.S. dollars)	December 31,

2015		12,565
2016		12,565
2017		815
2018		815
2019		815

		27,575

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Expenses

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Accounts Payable And Accrued Liabilities Disclosure [Text Block]

14.	Accrued Expenses

Accrued expenses consist mainly of expenses related to paid vacations, compensatory leaves with related social charges.

Accrued expenses comprises of the following:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Accrued compensation		2,440		3,792
Accrued social charges		3,566		1,866
Accrued Interest		521		-
Other		-		9
Total accrued expenses		6,527		5,667

Other current and Long Term liabilities

12 Months Ended

Dec. 31, 2014

Other Liabilities Disclosure [Abstract]

Other Liabilities Disclosure [Text Block]

15.	Other current and Long Term liabilities

15.1.

Other current liabilities

Other current liabilities comprise the following:

	December 31,
(In thousands of U.S. dollars)	2013		2014

R&D tax credit financing short term		7,121		5,382
Employee service award provision short term		285		-
Provision for retirement indemnity short term		-		55
Other		72		222
Total Other current liabilities		7,478		5,659

In 2012, the Company obtained an advance from OSEO, a governmental agency supporting innovation, for $5,848,000 (€4,432,000) secured against the research tax credits due to the company by the tax authorities for expenditure incurred in 2011. The interest rate applied is the monthly average of the Euro Interbank Offered Rate (EURIBOR) plus 0.9%. As of December 31, 2013 the total funding amounted to $13,234,000 of which $7,121,000 was classified as short term liability and $6,113,000 was classified as a long term liability (see note 15.2). As of December 31, 2014 the total funding amounted to $5,382,000 of which the totality was classified as short term liability.

The Service award provision is accrued over the respective service period (5, 10, 15 and 20 years). In October 2013, the Company terminated payment of the service award with an effective date of June 30, 2014 and as such, reversed the long term provision in operating expenses.

For the year ended December 31, 2013 the total provision amounted to $285,000 and is classified as short term.

15.2.

Other long term liabilities

Other long term liabilities are composed of the following:

	December 31,
(In thousands of U.S. dollars)	2013		2014

R&D tax credit financing long term		6,113		-
Provision for retirement indemnity (see note 20)		2,142		2,296
Other		59		37
Total Other long term liabilities		8,314		2,333

As of December 31, 2013 the total financing of the R&D tax credit amounted to $13,234,000 of which $6,113,000 was classified as a long term liability (see Note 15.1).

As of December 31, 2014 other long term liabilities are mainly composed of the provision for retirement indemnity (see note 21).

Long-term Debt

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Long Term Debt [Text Block]

16.	Long-term Debt:

Long-term debt comprises:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Oseo ANVAR loans (a)		2,553		1,927
French Ministry of Research (b)		2,033		1,790
Acquisition liability contingent consideration (c)		37,991		70,112
Acquisition liability note (c)		10,405		-
Acquisition liability warrant consideration (c)		10,497		34,542
Deerfield Facility agreement (d)		12,492		-
Deerfield Royalty agreement (d)		4,590		6,837
Broadfin Facility agreement (e)		2,767		-
Broadfin Royalty agreement (e)		2,187		3,259
Total		85,514		118,467
Current portion		19,194		42,332
Long-term portion		66,320		76,135

(a)

OSEO Anvar is an agency of the French government that provides financing to French companies for R&D. At December 31, 2013 and 2014, the Company had outstanding loans from Anvar of $2,553,000 and $1,927,000, respectively for various programs. These loans do not bear interest and are repayable only in the event the research project is technically or commercially successful. Repayment is scheduled to occur from 2014 through 2019.

(b)

In 2002, the Company received a loan of $464,000 from the French Ministry of Research on a research project (the “Proteozome” project) related to the development of new Medusa applications. Pursuant to the agreement, the Company is granted a loan equal to 50% of the total expenses incurred on this project over a three-year period beginning on January 2, 2002. The remainder of the advance of $1,707,000 was received in 2005. This loan is due for repayment in 2015. The loan is non-interest bearing and is repayable only in the event the research project is technically or commercially successful. The company has not received official acceptance notice of commercial and technical success.

(c)

The Acquisition liability relates to the acquisition by the Company through its wholly owned subsidiary Flamel US Holdings, Inc., or Flamel US, all of the membership interests of Éclat Pharmaceuticals, LLC (see note 2 Business combinations). In exchange for all of the issued and outstanding membership interests of Éclat Pharmaceuticals, Flamel US provided consideration consisting of:

a $12 million senior, secured six-year note that is guaranteed by the Company and its subsidiaries and secured by the equity interests and assets of Éclat;

two warrants to purchase a total of 3,300,000 American Depositary Shares, each representing one ordinary share of Flamel (“ADSs”); and

a commitment to make earn-out payments of 20% of any gross profit generated by certain Éclat Pharmaceuticals products and to pay 100% of any gross profit generated by Hycet® up to a maximum of $1 million. The Purchase Agreement also contains certain representations and warranties, covenants, indemnification and other customary provisions.

As of December 31, 2013, the fair value of the note was estimated using a probability-weighted discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a level 3 measurement as defined in ASC 820. The key assumptions are as follows: 20% discount rate, 100% probability of success. The note has no early redemption premium and was fully repaid in March 2014 generating an expense of $3.0 million.

The fair value of the warrants was determined by using a Black-Scholes option pricing model with the following assumptions for each of the years indicated:

	2013			2014
Share price		$8.05			$17.13
Risk-free interest rate		1.27	%		1.17	%
Dividend yield		-			-
Expected volatility		50.0	%		56.5	%
Expected term		4.3 years			3.3 years

Pursuant to guidance of ASC 815-40-15-7(i), the Company determined that the Warrants issued in March 2012 as consideration for the acquisition of Éclat could not be considered as being indexed to the Company’s own stock, on the basis that the exercise price for the warrants is determined in U.S. dollars, although the functional currency of the Company is the Euro. The Company determined that these warrants should be accounted as a debt instrument.

As of December 31, 2014, the deferred consideration fair value was estimated by using a discounted cash flow model based on probability-adjusted annual gross profit of each of the Éclat Pharmaceuticals products. A discount rate of 20% was used.

See also Note 21 – Fair Value of Financial Instruments.

(d)

On February 4, 2013 the Company concluded a $15 million debt financing transaction (Facility Agreement) with Deerfield Management, a current shareholder. Subject to certain limitations, the Company was permitted to use the funds for working capital, including continued investment in its R&D projects.

Consideration received was as follows:

$12.4 million for a Facility agreement of a nominal value of $15 million, including a premium on reimbursement of $2.6 million. The principal amount of the Loan must be repaid over four years as follows: 10% on July 1, 2014, and 20%, 30% and 40% on the second, third, and fourth anniversary, respectively, of the original disbursement date of the Loan. Notwithstanding the foregoing, the entire principal amount of the Loan may be repaid in whole or in part on any interest payment date occurring after December 31, 2013. Interest is payable quarterly, on the first business day of each January, April, July and October. The indebtedness was repaid on March 24, 2014 in its entirety; the accelerated reimbursement of this note resulted in interest expenses of $2.5 million.

$2.6 million for a Royalty agreement whereby, the Company’s wholly owned subsidiary Éclat, subject to required regulatory approvals and launch of product, is to pay a 1.75% Royalty of the net sales of certain products sold by Éclat and any of its affiliates until December 31, 2024.

The facility agreement is accounted for at amortized cost using an effective rate of 23%. The Company elected the fair value option for the measurement of the royalty liability.

The facility and royalty agreements are secured by the intellectual property and regulatory rights related to certain Éclat products and certain receivables.

As of December 31, 2014, the fair value of the Royalty was estimated using a probability-weighted discounted cash flow model based on probability adjusted projected annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals. This fair value measurement is based on significant inputs not observable in the market and thus represents a level 3 measurement as defined in ASC 820. The discount rate used is 20%.

See also Note 21 – Fair Value of Financial Instruments.

(e)

On December 3, 2013 the Company concluded with Broadfin Healthcare Master Fund, a current shareholder, a $15 million debt financing transaction (Facility Agreement) divided into 3 tranches of $5 million each, Under the terms of the Facility, upon closing Broadfin made an initial loan of $5.0 million and the Company was entitled to request, at any time prior to August 15, 2014, up to two additional loans in the amount of $5.0 million each, with funding subject to certain specified conditions. Subject to certain limitations, the Company was permitted to use the funds for working capital, including continued investment in its R&D projects.

Consideration received was as follows:

$2.8 million for a Facility agreement of a nominal value of $5 million, The principal amount of the Loan must be repaid over three years as follows: 100% on January 1, 2017. Notwithstanding the foregoing, the entire principal amount of the Loan may be repaid in whole or in part on any interest payment date occurring after December 31, 2013. Interest is payable quarterly, on the first business day of each January, April, July and October. The indebtedness was repaid on March 24, 2014 in its entirety; the accelerated reimbursement of this note resulted in interest expenses of $ 2.2 million.

$2.2 million for a Royalty agreement whereby, the Company’s wholly owned subsidiary Éclat, subject to required regulatory approvals and launch of product, is to pay a 0.834% Royalty of the net sales of certain products sold by Éclat and any of its affiliates until December 31, 2024.

The facility agreement is accounted for at amortized cost using an effective rate of 41%. The Company elected the fair value option for the measurement of the royalty liability.

The facility and royalty agreements are secured by intellectual property associated with the Company's Medusa technology and a junior lien on substantially all of the assets of the Borrowers, which were previously pledged in connection with the Deerfield facility, royalty and acquisition liabilities.

Total future payments on long-term debt for the next five years ending December 31 (assuming the underlying projects are commercially or technically successful for governmental research loans) are as follows:

(In thousands of U.S. dollars)

2015			45,722
2016			18,163
2017			11,834
2018			13,551
2019			8,758

			98,028

Earnings Per Share

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

17.	Earnings Per Share

The following is a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations:

	Year ended December 31,
(In thousands, except per share amounts)	2012		2013		2014

Numerator:

Net income (loss) from continuing operations	$	(4,740)	$	(46,511)	$	(88,924)
Net income (loss) from discontinuing operations	$	1,512	$	3,587	$	4,018
Denominator:
Weighted average shares outstanding used for basic earnings (loss) per share		25,135,416		25,450,175		36,214,384
Effect of dilutive securities:
Stock-options and warrants		-		-		-
Weighted average shares outstanding and dilutive securities used for diluted earnings (loss) per share		25,135,416		25,450,175		36,214,384

Earnings (loss) per ordinary share (Basic)
Continuing Operations	$	(0.19)	$	(1.83)	$	(2.45)
Discontinued Operations	$	0.06	$	0.14	$	0.11
Net income (loss)	$	(0.13)	$	(1.69)	$	(2.34)

Earnings (loss) per share (diluted) :
Continuing Operations	$	(0.19)	$	(1.83)	$	(2.45)
Discontinued Operations	$	0.06	$	0.14	$	0.11
Net income (loss)	$	(0.13)	$	(1.69)	$	(2.34)

For the years ended December 31, 2012, 2013 and 2014, the effects of dilutive securities were excluded from the calculation of earnings per share as a net loss was reported in these periods.

Options to purchase 6,396,240 shares of common stock at an average of $9.87 per share were outstanding during 2014. The options, which expire in December 2024, were still outstanding at the end of year 2014.

Shareholders' Equity

12 Months Ended

Dec. 31, 2014

Stockholders' Equity Note [Abstract]

Stockholders Equity Note Disclosure [Text Block]

18.	Shareholders’ Equity

18.1.

Preemptive subscription rights

Shareholders have preemptive rights to subscribe for additional shares issued by the Company for cash on a pro rata basis when the Company makes a share offering. Shareholders may waive such preemptive subscription rights at an extraordinary general meeting of shareholders under certain circumstances. Preemptive subscription rights, if not previously waived, are transferable during the subscription period relating to a particular offer of shares.

18.2.

Dividends

Dividends may be distributed from the statutory retained earnings, subject to the requirements of French law and the Company’s by-laws. The Company has not distributed any dividends since its inception, as the result of an accumulated statutory deficit of approximately $148.4 million at December 31, 2014. Dividend distributions, if any, will be made in euros. The Company has no plan to distribute dividends in the foreseeable future.

18.3.

Warrants

The effects of applying the fair value method provided in accordance with ASC 718 are shown in Note 7.

On June 25, 2010 the Company authorized the Directors of the Company, to subscribe to 250,000 warrants for a subscription price of €0.70 per warrant ($0.90). Each warrant is exercisable to purchase one Share at a price of €5.44 ($6.68). These warrants are issued for a four-year period and will vest over one year from the date of issuance. These warrants were subscribed in July 2010. As of December 31, 2014, 200,000 Warrants were exercised and 50,000 warrants were cancelled.

On June 24, 2011 the Company authorized the Directors of the Company, to subscribe to 350,000 warrants for a subscription price of €0.47 per warrant ($0.67). Each warrant is exercisable to purchase one Share at a price of €3.54 ($5.03). These warrants are issued for a four-year period and will vest over one year from the date of issuance. 300,000 warrants were subscribed in July 2011. As of December 31, 2014, 200,000 Warrants were exercised.

On March 13, 2012, in connection with the acquisition of Éclat Pharmaceutical, Flamel issued to Breaking Stick LLC (formerly Éclat Holdings LLC), two six-year warrants to purchase an aggregate of 3,300,000 ADSs, each representing one ordinary share, of Flamel. One warrant is exercisable for 2,200,000 ADSs at an exercise price of $7.44 per ADS, and the other warrant is exercisable for 1,100,000 ADSs at an exercise price of $11.00 per ADS. Pursuant to the guidance of ASC 815-40-15-7 the Company determined that the warrants should be accounted for as a liability (see note 16 Long Term Debt).

On June 20, 2013, the Company authorized the Directors of the Company, to subscribe to 270,000 warrants for a subscription price of €0.43 per warrant ($0.57). These warrants are issued for a four-year period and will vest over one year from the date of issuance. Each warrant is exercisable to purchase one Share at a price of €4.58 ($6.14). These warrants are issued for a four-year period and will vest over one year from the date of issuance. 180,000 warrants were subscribed in July 2013.

On June 20, 2013, the Company authorized the scientific advisory board members, excluding directors, to subscribe to 20,000 warrants for a subscription price of €0.43 per warrant ($0.57) as an offset to receivables for services provided by members of the scientific advisory board. These warrants are issued for a four-year period and will vest immediately. 20,000 warrants were subscribed in August 2013.

On June 24, 2014, the Company authorized the Directors of the Company, to subscribe to 300,000 warrants for a subscription price of €0.89 per warrant ($1.22). These warrants are issued for a four-year period and will vest over one year from the date of issuance. Each warrant is exercisable to purchase one Share at a price of €10.94 ($14.87). These warrants are issued for a four-year period and will vest over one year from the date of issuance. 298,000 warrants were subscribed in September 2014.

On exercise of warrants by beneficiaries, the Company issues new shares.

18.4.

Stock options

The Company issued stock options under plans approved by shareholders in 1990, 1993, 1996, 2000, 2001, 2003, 2004, 2005, 2007, 2010, 2012, 2013 and 2014. The option terms provide for exercise within a maximum 10-year term as from the date of grant. Generally, each option vests no more than four years from the date of grant.

In January 1997, the French parliament adopted a law that requires French companies and beneficiaries to pay social contributions, which generally represent 45% of the taxable salary, on the difference between the exercise price of a stock option and the fair market value of the underlying shares on the exercise date if the beneficiary sells the stock before a four-year period following the grant of the option (five years for options granted before 2000). This law is consistent with personal income tax law that requires individuals to pay income tax on the difference between the option exercise price and the fair value of the shares at the sale date if the shares are sold within four years of the option grant. The law applies to all options exercised after January 1, 1997. The Company has instituted an internal rule whereby, whilst remaining an employee of the Company, an individual may not sell the underlying share within four years of the option being granted.

In December 2007, the French parliament adopted a law that requires French companies to pay an additional social security contribution of 10% for each option granted, based on either the fair value of the option or 25% of share price at date of grant. This is applicable on all options granted since October 16, 2007. In December 2010, the French parliament introduced a contribution rate of 14% depending on the value of the grant. In July 2012 this rate was increased to 30%.

On exercise of stock options by beneficiaries, the Company issues new shares.

18.5.

Free Share Awards

On June 24, 2014, the shareholders of the Company authorized the issuance of 250,000 new shares that the Board of Directors was authorized to award and issue free of charge to the employees, or certain categories of them, of the Company or of the companies or organizations affiliated with it under the conditions set forth in Article L.225-197-2, 1° of the French Commercial Code and the corporate officers of the Company or organizations affiliated with it and that satisfy the conditions set forth in Article L.225-197-1, II of the French Commercial Code as compensation for services rendered. Under the terms of the awards the shares are definitively owned by French and Ireland tax resident beneficiaries two years and for US tax resident beneficiaries four years after grant and the Company issues new shares. French tax resident beneficiaries are required to retain the shares for two additional years after definitive acquisition. This authorization supersedes any unused portion of the previous authorizations granted to the Board of Directors by the shareholders.

In December 2007, the French parliament adopted a law that requires French companies to pay an additional social contribution of 10% for each share granted, based on the share price at date of grant. In December 2010, the French parliament introduced a contribution rate of 14% depending of the value of the grant. In July 2012 the contribution rate was raised to 30%.

On December 11, 2009 the Company granted 295,000 free share awards to officers and employees. On December 11, 2011 the Company issued 267,400 new shares related to this grant. On December 11, 2013, the Company issued 10 000 new shares related to this grant.

On December 6, 2010 the Company granted 230,000 free shares awards to officers and employees. On December 6, 2012 the Company issued 208,150 new shares related to this grant. On December 11, 2014, the Company issued 6 000 new shares related to this grant.

On December 7, 2011 the Company granted 200,000 free shares to officers and employees. On December 31, 2012 the Company issued 45,000 new shares related to this grant. On December 7, 2013 the Company issued 137,150 new shares related to this grant.

On December 10, 2012 the Company granted 189,700 free shares to officers and employees. On December 11, 2014 the Company issued 150,600 new shares related to this grant.

On December 12, 2013 the company granted 192,500 free shares to officers and employees.

On December 11, 2014 the company granted 188,300 free shares to officers and employees.

18.6.

Restricted Shares

On June 20, 2013, the shareholders of the Company authorized the issuance of 200,000 new shares that the Board of Directors was authorized to award and issue to any person or company who may sold or transfer to the Company asset(s), including any shares, representing immediately or overtime, their ownership or voting rights in any commercial enterprise. This authorization was granted for a term of eighteen (18) months. As of December 20, 2014, no shares have been issued as a result of this authorization.

18.7.

Accumulated other comprehensive income

The components of accumulated other comprehensive income is as follows:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Foreign currency translation		10,815		(7,225)
Unrealized gain (loss) on marketable secuirities				(198)

Total		10,815		(7,423)

18.8.

Capital raise

During the twelve month period ended December 31, 2014, the Company issued 12,400,000 shares as a result of an underwritten public offering in March 2014. The offering price to the public was $9.75 per American Depositary Share, each representing one ordinary share (“ADS”), and included payment of a commission of $0.585 per ADS. Total increase in shareholders equity amounted to $115.2 million, including $113.6 million in net proceeds, ($0.7) million in issuance costs and $2.4 million in tax relief from issuance costs and underwriter commission.

In December 1,026,364 shares were acquired by Recipharm as a private placement. The offering price to Recipharm AB was $12.71 per American Depositary Share, each representing one ordinary share (“ADS”). Total net proceeds amounted to $13,049,000.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Income taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

19.	Income taxes

Income (loss) before income taxes comprises the following:

	Year ended December 31,
(in thousands of U.S. dollars)	2012			2013			2014

France		(15,755	)		(3,889	)		(392	)
United States		6,286			(53,864	)		(89,939	)
Total	$	(9,469	)	$	(57,753	)	$	(90,331	)

A reconciliation of income tax benefit (provision) computed at the French statutory rate (33.33%) and the US statutory rate (40%) to the income tax benefit is as follows:

	Year ended December 31,
(in thousands of U.S. dollars)	2012			2013			2014

Income tax benefit (provision) computed at the statutory rate (US & France)		2,737			22,842			36,106
Deferred Tax Allowance		(5,251	)		(1,930	)		(10,973	)
Business Tax		(59	)		(76	)		(1,400	)
Non Taxable remeasurement of fair value accounting of earn out		7,303			(9,592	)		(22,326	)
Total	$	4,729		$	11,244		$	1,407

License fees, milestone and royalties payments may be subject to a withholding tax depending on the tax rules of the country in which the licensee is located. In December 2009, with effect from January 1, 2010 the French authorities abolished the previous business tax and introduced the "Contribution Economique Territoriale" comprised of two components. One of these components is based upon a measure of income and therefore results in income tax accounting. For the year ended December 31, 2012, 2013 and December 31, 2014 the amount of this component was $29,000, $76,000 and $1,400,000 respectively. The increase in business tax for the year ended December 31, 2014 is due to the taxable income generated from French based operations following the divestiture of the Pessac Facility and income generated from the sale of intellectual property to the Irish operations.

Significant components of the Company's deferred taxes consist of the following:

	December 31,
(In thousands of U.S. dollars)	2012			2013			2014

Deferred income tax assets:
Net taxable operating loss carry-forwards (not utilized)		65,657			81,769			66,167
Other deferred income tax assets		3,656			1,898			1,052
Valuation allowance		(64,356	)		(69,940	)		(57,980	)
Net deferred income tax assets		4,957			13,728			9,238
Deferred income tax liabilities		(19,086	)		(16,534	)		(9,238	)
Deferred income taxes, net		(14,130	)		(2,806	)		-

The Company has provided valuation allowances covering 100% of net deferred tax assets generated from its activities in France and US due to the Company's history of losses. As of December 31, 2012 and 2013, deferred tax assets have been recognized on losses from US operations to the extent of the deferred tax liabilities.

As of December 31, 2014, the Company had $142.2 million in French net operating losses carry-forwards. Annual utilization is normally limited to €1,000,000 plus fifty per cent (50%) of any taxable income in excess of this threshold. The net operating losses carry-forwards are forfeited on substantial change in operations. Substantial change in operations occurs when the following criteria are met:

Reduction of more than fifty per cent (50%) in revenues from one fiscal year to another,

Reduction of more than fifty per cent (50%) in the average employees employed or in the gross book value of assets from one fiscal year to another.

Following the divestiture of the Pessac Facility the above criteria were met for the French operations. However, the Company filed a request with the French tax administration in November 2014, in accordance with French tax legislation, to limit the forfeiture of the net operating losses carry-forwards to those pertaining to the Pessac Facility and to maintain the net operating losses carry-forwards pertaining to the R&D operations that remain in the French operations. The request was filed on the basis that the divestiture was part of a strategic shift in the Company operations to maintain the operations and employment related to the R&D operations in France and with an objective of becoming profitable. The Company expects to receive a response from the French tax administration in the next twelve months. The ability for the Company to carry forward net operating losses from French operations is deemed uncertain.

As of December 31, 2014, the Company had $46.9 million in US net operating losses carry-forwards which expire from 2030 to 2032, for which utilization of pre-acquisition tax losses of $4.9 million is limited to $1.8 million per year.

The decrease in available net operating losses carry-forwards in 2014 is due to taxable income from French operations in 2014 of $69.3 million, on which $35.3 million net operating losses have been utilized, offset by an increase in net operating losses from US operations of $10.2 million.

The French government provides tax credits to companies for spending on innovative R&D. These credits are recorded as an offset of R&D expenses (see note 5) and are credited against income taxes payable in each of the four years after being incurred or, if not so utilized, are recoverable in cash. As of December 31, 2014, Flamel had total net income tax payable of $7.6 million reflecting income tax payable of $11.7 million, offset by a research tax credit of $5.5 million and business tax payable of $1.5 million. The income tax will be paid in May 2015.

On December 16, 2014, Flamel transferred all of its intangible property from its French entity to its Irish-based entity as a part of a global reorganization. The intangible property includes patents on drug delivery platforms, clinical data sets and other intangible assets related to the pipeline of proprietary products in development. As of December 31, 2014, and as a result of the intra-entity transaction, an income tax expense has been deferred for $14.1 million, of which $1.0 million is classified as prepaid expenses and $13.1 million as a long term asset. The deferred tax expense will be amortized over the tax life of the asset which is 14.3 years, at a rate of 7% per year and result in tax relief of $9.7 million from 2015 to 2029. No deferred tax asset has been recognized on this intra-entity transaction.

As of December 31, 2014, Flamel had a research tax receivable of $5.9 million from the tax credit generated in 2011. In 2012, the Company obtained an advance from OSEO, a governmental agency supporting innovation, secured against the Research tax credit generated in fiscal year 2011(see Note 15.1). Generally, if these credits are not applied against future income taxes, they will be received as cash payments in the fourth year after the credit is earned.

The scheduled payments are shown in the following table:

(In thousands of U.S. dollars)	December 31,
2015		5,930
Total current portion		5,930

Employee Retirement plans

12 Months Ended

Dec. 31, 2014

Compensation and Retirement Disclosure [Abstract]

Pension And Other Postretirement Benefits Disclosure [Text Block]

20.	Employee Retirement plans

In accordance with French law, post-retirement benefits for most of the Company’s employees are sponsored by the relevant government agencies in France. The Company’s liability with respect to these plans is generally limited to specific monthly payroll deductions. Consequently, there is no additional liability in connection with these plans. Expenses recognized for these plans were $815,000 in 2012, $701,000 in 2013, and $719,000 in 2014.

French law requires the Company to provide for the payment of a lump sum retirement indemnity to French employees based upon years of service and compensation at retirement. Benefits do not vest prior to retirement. The Company’s benefit obligation was $2,142,000 and $2,350,000 as of December 31, 2013 and 2014, respectively. Any actuarial gains or losses are recognized in the income statement in the period when they occur.

In 2008, 2010 and 2013, the French Government reinforced legislation regarding an employer’s ability to make employees retire and the final age for retirement. As such the retirement indemnity has been calculated on the assumption of voluntary retirement and the impact on the benefit obligation was recognized as an actuarial loss.

The benefit obligation is calculated as the present value of estimated future benefits to be paid, using the following assumptions:

	2012		2013		2014
Average increase of salaries		3%		3%		3%
Discounted interest rate		3%		3.25%		1.49%
Turn over		actuarial standard and average of the last 5 years		actuarial standard and average of the last 5 years		actuarial standard and average of the last 5 years

Age of retirement		60 to 65 years actuarial standard based on age and professional status		60 to 65 years actuarial standard based on age and professional status		60 to 65 years actuarial standard based on age and professional status

Changes in the funded status of the benefit plans were as follows:

	December 31,
In thousands of U.S. dollars	2013		2014

Benefit obligations at beginning of year		1,159		2,142
Service cost		1,106		99
Interest cost		36		36
Plan amendments		-		-
Benefits paids		-		(87)
Actuarial loss (gain)		(233)		460
Exchange rate changes		74		(300)
Benefit obligations at end of year		2,142		2,350

The Company does not have a funded benefit plan and the lump sum retirement indemnity is accrued on the balance sheet as a liability.

The future expected benefits to be paid over the next five years and for the five years thereafter is as follows:

Future expected payment of benefits:	Year Ending:
In thousands of U.S. dollars
	12/31/2015	55
	12/31/2016	-
	12/31/2017	-
	12/31/2018	-
	12/31/2019	12
	Next 5 Years	150

In the United States, the Company previously sponsored a defined contribution retirement plan for certain employees located in the United States. The contribution is the lesser of 25% of an employee’s wages or $49,000 in 2012. The Company made and accrued contributions of approximately $140,000 in 2012.

Fair value of financial instruments

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

21.	Fair value of financial instruments:

At December 31, 2013 and 2014, the carrying values of financial instruments such as cash and cash equivalents, trade receivables and payables, other receivables and accrued liabilities and the current portion of long-term debt approximated their market values, based on the short-term maturities of these instruments.

As noted in Note 9, the company calculates fair value for its marketable securities based on quoted market prices for identical assets and liabilities which represents Level 1 of ASC 820-10 fair value hierarchy.

At December 31, 2013 and 2014 the fair value of long-term debt and long term receivables was comparable with their carrying values.

The following table presents information about the Company securities based on quoted market prices for identical assets and liabilities for 2014 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.

In thousands of U.S. Dollars	Net Carrying Value as of	Fair Value Measured and Recorded Using			Operational Gain (losses) recognized in	Financial Gain (losses) recognized in
	December 31, 2014	Level 1	Level 2	Level 3	earnings	earnings	Total

Assets
Cash and cash equivalent	39,760	39,760	-	-	-	-	-
Marketable securities	53,074	53,074	-	-	-	547	547
Total					-	547	547
Liabilities
Acquisition liability contingent consideration (a)	70,112	-	-	70,112	(33,445)	-	(33,445)
Acquisition liability note (b)	-	-	-	-	(3,013)	-	(3,013)
Acquisition liability warrant consideration (c)	34,542	-	-	34,542	(24,045)	-	(24,045)
Deerfield Royalty Agreement (d)	6,837			6,837	-	(2,386)	(2,386)
Broadfin Royalty Agreement (e)	3,259			3,259	-	(1,139)	(1,139)
Total					(60,503)	(3,525)	(64,028)

The following table presents information about the Company securities based on quoted market prices for identical assets and liabilities for 2013 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.

(in thousands)	Net Carrying Value as of	Fair Value Measured and Recorded Using			Operational Gain (losses) recognized in	Financial Gain (losses) recognized in
	December 31, 2013	Level 1	Level 2	Level 3	earnings	earnings	Total
Assets
Cash and cash equivalent	6,636	6,636	-	-	-	-	-
Marketable securities	401	401	-	-	-	-	-

Liabilities
Acquisition liability contingent consideration (a)	37,991	-	-	37,991	(14,768)	-	(14,768)
Acquisition liability note (b)	10,405	-	-	10,405	(5,027)	-	(5,027)
Acquisition liability warrant consideration (c)	10,497	-	-	10,497	(8,340)	-	(8,340)
Deerfield Royalty Agreement (d)	4,590			4,590	-	(1,991)	(1,991)
Broadfin Royalty Agreement (e)	2,187			2,187	-		-
Total					(28,135)	(1,991)	(30,126)

The fair value of the financial instruments in connection with the acquisition of Éclat (see note 2 Business Combinations) are estimated as follows:

(a)

Acquisition liability deferred consideration: the fair value is estimated using a discounted cash flow model based on probability adjusted projected annual gross profit of each of the products which formed the project portfolio at the time of acquisition of Éclat Pharmaceuticals (Note 16 Long Term Debt). The fair value of the deferred consideration will change over time in accordance with the changes in market conditions and thus business plan projections as the relate to market size, market share, product pricing, competitive landscape, gross profit margins expected for each of the products.

(b)

Acquisition liability Note: the Company uses a probability-weighted discounted cash flow model (see note 16 Long Term Debt).

(c)

Acquisition liability warrant consideration: the Company uses a Black-Scholes option pricing model. The fair value of the warrant consideration will change over time depending on the volatility and share price at balance sheet date (see note 16 Long Term Debt).

(d)

Deerfield Royalty Agreement: the fair value is estimated using a discounted cash flow model based on probability adjusted projected annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals (see Note 16 Long Term Debt).

(e)

Broadfin Royalty Agreement: the fair value is estimated using a discounted cash flow model based on probability adjusted projected annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals (see Note 16 Long Term Debt).

The following tables provide a reconciliation of fair value for which the Company used Level 3 inputs:

	Acquisition
	Liabilities
Liability recorded upon acquisition	$	(50,927)
Operational gain (loss) recognized in earnings for fiscal year 2012		18,993
Operational gain (loss) recognized in earnings for fiscal year 2013		(28,135)
Payment deferred consideration (Hycet)		841
Payment interest on acquisition liability note		335
Net carrying value at January 1, 2014	$	(58,893)

Operational gain (loss) recognized in earnings for fiscal year 2014		(60,503)
Reimbursment of acquisition liability note		12,000
Payment of interest on acquisition liability note		1,389
Payment of deferred consideration		1,354
Net carrying value at December 31, 2014	$	(104,653)

	Deerfield Royalty		Broadfin Royalty
	Agreement		Agreement
Liability recorded upon execution of Agreeement	$	(2,600)	$	(2,187)
Interest expense recognized in earnings for fiscal year 2013		(1,990)		-
Interest expense recognized in earnings for fiscal year 2014		(2,386)		(1,139)
Payment of Royalty		140		67
Net carrying value at December 31, 2014	$	(6,837)	$	(3,259)

The acquisition liabilities, consisting of the note, warrants and deferred consideration, and the Deerfield and Broadfin Royalty agreements all of which are classified as long-term debt, are measured at fair value and the income or expense may change significantly as assumptions regarding the valuations and probability of successful development and approval of products in development vary.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments And Contingencies Disclosure [Text Block]

22.

Commitments and Contingencies

22.1.

Operating leases

The Company leases its facilities and certain equipment under non-cancelable operating leases, which expire through 2016. Future minimum lease payments under operating leases due for the fiscal years ending December 31, 2014 are as follows:

In thousands of U.S. Dollars	December 31,
2015		841
2016		177
TOTAL		1,018

Rental expense for the years ended December 31, 2012, 2013 and 2014 was approximately $863,000, $759,000 and $844,000, respectively.

22.2.

Litigation

While we may be engaged in various claims and legal proceedings in the ordinary course of business, we are not involved (whether as a defendant or otherwise) in and we have no knowledge of any threat of, any litigation, arbitration or administrative or other proceeding that management believes will have a material adverse effect on our consolidated financial position or results of operations.

22.3.

Purchase Commitments

The Company has commitments to purchase to acquire services from Recipharm Pessac for a total of $22.5 million for a five year period commencing January 1, 2015 (see Note 6 Discontinued Operations) and to purchase one batch per year for the next five years of the generic pharmaceutical product it markets for $46,000 per year.

Industry and geographic information

12 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

23.

Industry and geographic information

The Company operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology.

Operations outside of France consist principally of the operations of Éclat Pharmaceuticals acquired in March 2012 which had sales amounting to $560,000 in 2012; $983,000 in 2013 and $11,920,000 in 2014 (see note 4 product sales).

Revenues by geographic location of customers are as follows:

(in thousands of U.S. dollars)	As of December 31,
	2012		2013		2014
Revenues
USA		3,894		3,368		14,302
Europe		3,640		811		473
Total Revenues		7,534		4,179		14,775

The following is a summary of long-lived assets by geographic location:

(in thousands of U.S. dollars)			As of December 31,
	2012		2013		2014

Long-lived assets:
USA	$	60,260	$	58,868	$	47,077
France	$	31,966	$	2,307	$	1,703
Total long-lived assets	$	92,226	$	61,175	$	48,780

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Related Party Transactions

12 Months Ended

Dec. 31, 2014

24.

Related Party Transactions

In March 2012, we acquired, through our wholly owned subsidiary Flamel US Holdings, all of the membership interests of Éclat from Éclat Holdings, an affiliate of Flamel’s largest shareholder Deerfield Capital L.P., see “note 2 - Business Combinations”. The consideration consisted of a $12 million senior, secured six-year note that is guaranteed by us and our subsidiaries and secured by the equity interests and assets of Éclat, two warrants to purchase a total of 3,300,000 ADSs of Flamel and commitments to make earnout payments of 20% of any gross profit generated by certain Éclat products and 100% of the gross profit generated by our former product Hycet®, up to a maximum of $1 million, which we sold in 2013. The $12 million senior note was repaid in full in March 2014 using the net proceeds from our public sale of ADSs and the Hycet asset was disposed of in November 2013. Upon closing of the acquisition, Mr. Anderson, the Chief Executive Officer of Éclat, was appointed Chief Executive Officer of Flamel. Mr. Anderson retains a minority interest in Éclat Holdings, (now renamed Breaking Stick Holdings, LLC), and does not have the ability to control this entity by virtue of his minority interest. The senior secured note was repaid in full in March 2014 (see also note 16. Long Term debt).

On February 4, 2013, we entered into a Facility Agreement (the “Deerfield Facility”), through Flamel US with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (together, the “Deerfield Entities”) providing for debt financing of $15 million by the Deerfield Entities (the “Loan”). The loan was repaid in full in March 2014 using the net proceeds from our public sale of ADSs. The Deerfield Facility was subject to certain limitations, and allowed us to use the funds for working capital, including continued investment in our R&D projects. Interest accrued at 12.5% per annum to be paid quarterly in arrears, commencing on April 1, 2013. Pursuant to the Deerfield Facility, we were required to pay the Deerfield Entities a fee of $112,500 for entering into the transaction and to reimburse the Deerfield Entities for legal costs and expenses incurred in effecting the transaction.

In conjunction with our entry in the Deerfield Facility, Éclat entered into a Royalty Agreement with Horizon Santé FLML, Sarl and Deerfield Private Design Fund II, L.P., both affiliates of the Deerfield Entities (together, “Deerfield PDF/Horizon”). The Royalty Agreement provides for Éclat to pay Deerfield PDF/Horizon 1.75% of the net sales price of the products sold by us and any of our affiliates until December 31, 2024, with royalty payments accruing daily and paid in arrears for each calendar quarter during the term of the Royalty Agreement. See also note 16 Long Term Debt.

We have also entered into a Security Agreement dated February 4, 2013 with Deerfield PDF/Horizon, whereby Deerfield PDF/Horizon was granted a security interest in the intellectual property and regulatory rights related to the products to secure the obligations of Éclat and Flamel US, including the full and prompt payment of royalties to Deerfield PDF/Horizon under the Royalty Agreement.

On December 3, 2013, we and certain of our U.S. subsidiaries entered into a Facility Agreement (the “Broadfin Facility”) with Broadfin Healthcare Master Fund, Ltd. (“Broadfin”) providing for loans by Broadfin in an aggregate amount not to exceed $15.0 million. The loans under the Facility and the obligations under the Royalty agreement were secured by a first priority security interest in intellectual property associated with our Medusa technology and a junior lien on substantially all of the assets of the borrowers, which were previously pledged in connection with the Deerfield Facility, the Royalty Agreement and the notes issued in connection with the Éclat acquisition. In addition, we agreed to grant a junior lien on certain equipment located in France, if such equipment is pledged under the Deerfield Facility and/or the Éclat note.

Under the terms of the Broadfin Facility, upon closing Broadfin made an initial loan of $5.0 million and we had the ability to request, at any time prior to August 15, 2014, up to two additional loans in the amount of $5.0 million each, with funding subject to certain specified conditions. We had the ability to prepay the outstanding loans under the Broadfin Facility at any time, without prepayment penalty and the full $5.0 million outstanding was subsequently repaid using a portion of the net proceeds from our public sale of ADSs in March 2014. Prior to repayment, interest accrued on the loan under the Broadfin Facility at a rate of 12.5% per annum, payable quarterly in arrears, commencing on January 1, 2014.

In connection with entering into the Broadfin Facility, we also entered into a Royalty Agreement with Broadfin, dated as of December 3, 2013 (the “Broadfin Royalty Agreement”). Pursuant to the Broadfin Royalty Agreement, we are required to pay a royalty of 0.834% on the net sales of certain products sold by Éclat Pharmaceuticals, LLC and any of its affiliates until December 31, 2024. See also note 16 Long-Term Debt.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Post Balance Sheet Events

12 Months Ended

Dec. 31, 2014

Subsequent Events [Abstract]

Subsequent Events [Text Block]

25.

Post Balance Sheet Events

On January 15, 2015, the Wholesale Acquisition Cost (“WAC”) for Bloxiverz^® was increased to $98.75 per vial from $35.80 subsequent to the approval by the FDA of APP’s NDA for neostigmine methylsulfate product. The price increase is effective on contract prices with hospitals and GPOs 30 days after announcement of the increased WAC. Due to arrangements in place with wholesalers, wholesalers will receive a chargeback in the amount of $19.0 million for units sold by the wholesalers for the period from January 16 to February 15, 2015, which will be recognized as a reduction in revenue for the three-month period ended March 31, 2015.

Nature of business and summary of significant accounting policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Nature Of Business Policy [Policy Text Block]

1.1.

Nature of business

Use of Estimates, Policy [Policy Text Block]

1.2.

Management estimates

The accompanying consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP).

Discontinued Operations, Policy [Policy Text Block]

1.3.

Discontinued Operations

The company divested its development and manufacturing facility in Pessac, France on December 1, 2014 to Recipharm.

Going Concern [Policy Text Block]

1.4.

Going concern

Consolidation, Policy [Policy Text Block]

1.5.

Principles of consolidation

Foreign Currency Transactions and Translations Policy [Policy Text Block]

1.6.

Translation of financial statements of foreign entities and foreign currency transactions

Transaction gains and losses are reflected in the statement of operations.

The Company has not undertaken hedging transactions to cover its currency translation exposure.

Revenue Recognition, Policy [Policy Text Block]

1.7.

Revenue recognition

Revenue includes upfront licensing fees, milestone payments for R&D achievements, compensation for the execution of R&D activities and sales of pharmaceutical products.

The Company uses a Multiple Attribution Model, referred to as the milestone-based method:

⋅

When Flamel receives revenue under signed feasibility study agreements, revenue is then recognized over the term of the agreement as services are performed.

Governmental Grants Policy [Policy Text Block]

1.8.

Governmental Grants

The Company receives financial support for various research or investment projects from governmental agencies.

Research and Development Expense, Policy [Policy Text Block]

1.9.

R&D costs

The Company does not disclose research development costs per partner funded contract and does not believe such disclosure would be material to investors.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

1.10.

Concentration of credit risk

The Company's cash and cash equivalents are mainly deposited with Morgan Stanley, Crédit Agricole, HSBC, and Commerce Bank.

The marketable securities issued by Morgan Stanley and from Crédit Agricole have strong credit ratings.

Earnings Per Share, Policy [Policy Text Block]

1.11.

Earnings per share

Cash and Cash Equivalents, Policy [Policy Text Block]

1.12.

Cash and cash equivalents

Cash and cash equivalents consist of cash on hand, cash on deposit and fixed term deposit being highly liquid investments with a maturity of three months or less at the date of purchase.

Marketable Securities, Policy [Policy Text Block]

1.13.

Marketable securities

Trade and Other Accounts Receivable, Policy [Policy Text Block]

1.14.

Accounts Receivable

Inventory, Policy [Policy Text Block]

1.15.

Inventories

Property, Plant and Equipment, Policy [Policy Text Block]

1.16.

Property and equipment

Property and equipment is stated at historical cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:

Land and buildings		20 years
Laboratory equipment		4 - 8 years
Office and computer equipment		3 years
Furniture, fixtures and fittings		5-10 years

Goodwill and Intangible Assets, Policy [Policy Text Block]

1.17.

Goodwill and intangible assets

Changes in market conditions could have a major impact on the valuation of these assets and could result in additional impairment losses.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

1.18.

Impairment of Long-Lived Assets

Income Tax, Policy [Policy Text Block]

1.19.

Income taxes

Research Credit Tax Policy [Policy Text Block]

1.20.

Research credit tax

Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]

1.21.

Employee stock options and warrants

The Company accounts for Stock based compensation based on grant-date fair value estimated in accordance with ASC 718.

The Company estimated the fair value of stock options and warrants using a Black-Scholes option-pricing valuation model (“Black-Scholes model”).

The Company recognizes compensation cost, net of an estimated forfeiture rate, using the accelerated method over the requisite service period of the award.

Debt, Policy [Policy Text Block]

1.22.

Long-Term Debt

New Accounting Pronouncements, Policy [Policy Text Block]

1.23.

Recent Accounting Pronouncements

Nature of business and summary of significant accounting policies (Tables)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Property, Plant and Equipment, Schedule of Significant Acquisitions and Disposals [Table Text Block]

Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:

Land and buildings		20 years
Laboratory equipment		4 - 8 years
Office and computer equipment		3 years
Furniture, fixtures and fittings		5-10 years

Business combinations (Tables)

12 Months Ended

Dec. 31, 2014

Business Combinations [Abstract]

Schedule Of Acquisition Liabilities [Table Text Block]

The acquisition-date fair value of the consideration transferred totaled $50,927,000 which consisted of the following:

(Amounts in thousands of US dollars)
Note		5,625
Warrants		12,065
Deferred consideration		33,237
Total acquisition liabilities		50,927

Schedule Of Valuation Assumptions [Table Text Block]

The fair value of the warrants was determined by using a Black-Scholes option pricing model with the following assumptions:

Share price	$	7.29
Risk-free interest rate		2.00	%
Dividend yield		-
Expected volatility		56.26	%
Expected term		6.0 years

Product sales and services (Tables)

12 Months Ended

Dec. 31, 2014

Product sales and services [Abstract]

Schedule Of Recognized Net Sales [Table Text Block]

Year Ended December 31, 2014 ($ in thousands)	Sales Recognized in the Current Period		Deferred Sales		Deferred Sales reclassed against outstanding Accounts Receivable		Ending Deferred Sales for which Payment has been Collected
Gross Sales	$	15,789	$	11,051	$	(9,420)	$	1,630
Less:
Chargebacks	$	3,363	$	132	$	(23)	$	109
Wholesaler distribution fees		1,470		972		(823)		149
Cash discounts and other		326		225		(188)		37
Fees and returns		419		-		-		-
Net Sales	$	10,211	$	9,722	$	(8,386)	$	1,335

Schedule of Changes In Reserve Or Liability [Table Text Block]

A summary of fiscal year 2014 changes for each reserve or liability for Bloxiverz^®, Vazculep™ and the Company’s generic pharmaceutical product is as follows:

Year Ended December 31, 2014 ($ in Thousands)	Beginning Balance		Additions		Reductions		Ending Balance
Accounts Receivable Reserves:
Chargebacks	$	483	$	4,832	$	(4,307)	$	1,008
Wholesaler distribution fees		102		2,619		(1,642)		1,079
Cash Discounts and other		28		733		(508)		252

Liabilities:
GPO fees	$	6	$	267	$	(161)	$	112
Sales returns		42		200		(8)		234
Medicaid rebates		37		16		(29)		24
Total		698		8,667		(6,656)		2,709

R&D expenses (Tables)

12 Months Ended

Dec. 31, 2014

Research and Development Expenses [Abstract]

Research and Development Arrangement, Contract to Perform for Others [Table Text Block]

Total R&D expenditures can be disaggregated in the following significant type of expenses ($USD in millions):

In millions of U.S. Dollars	2012		2013		2014
R&D Expenses		21.2		21.8		22.8
R&D Tax Credit		(6.5)		(5.8)		(5.5)
Grants		(0.1)		-		-
Total		14.6		16.0		17.3

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2014

Discontinued Operations and Disposal Groups [Abstract]

Schedule Of Disposal Groups, Including Discontinued Operation Income Statement [Table Text Block]

Summary results of operations for the Pessac business were as follows:

	Fiscal Year
In thousands of U.S. Dollars	2012		2013		2014

Revenues	$	18,570	$	18,265	$	14,967
Income (loss) from operations		1,550		3,667		(875)
Gain (loss) on disposal		-		-		5,007
Interest Expense		(11)		(9)		(4)
Income taxes		(27)		(74)		(110)
Income (loss) from discontinued operations, net of tax	$	1,512	$	3,584	$	4,018

Schedule Of Disposal Groups, Including Discontinued Operation Balance Sheets [Table Text Block]

Carrying amounts of major classes of assets and liabilities classified as held for sale in the statement of financial position are as follows:

	December 31,
In thousands of U.S. Dollars	2013		2014

Accounts receivable, net	$	-	$	730
Inventories		1,352		-

Total major classes of current assets of the discontinued operations		1,352		730

Net Property, plant and equipment		15,044		-
Total major classes of non current assets of the discontinued operations		15,044		-
Total assets of the disposal group classified as held for sale		16,396		730

Current portion of capital lease obligations		69
Accounts payable		-		168
Other current liabilities		832		-
Total major classes of Current Liabilities of the discontinued operations		901		168

Capital lease obligations, less current portion		88		-
Other liabilities		7,626		-
Total major classes of Non-Current Liabilities of assets Held for sale		7,714		-
Total liabilities of the disposal group classified as held for sale		8,615		168

Schedule Of Disposal Groups, Including Discontinued Operation Cash Flows [Table Text Block]

The major cash-flows related to Discontinued Operations presented in the statement of cash-flows are as follows

	2012		2013		2014
Capital Expenditures	$	766	$	872	$	1,271
Depreciation and Amortization		1,910		1,751		1,709
Operating and Investing non-cash elements		(975)		(676)		(740)

Schedule Of Supply And Services Of Products [Table Text Block]

The minimum amount of services per year, for a cumulative total of $22.5 million as follows:

First Year	$	4.25 millions
Second Year	$	4.25 millions
Third Year	$	4.25 millions
Fourth and Fifth Year each	$	4.86 millions

Stock based compensation (Tables)

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The weighted-average assumptions on grants made in each of the following years were:

	Year Ended December 31
	2012			2013			2014
Weighted-average expected life (years)	$	5.70		$	5.43		$	4.26
Expected volatility rate		62.50	%		61.00	%		61.00	%
Expected dividend yield		-			-			-
Risk-free interest rate		0.95	%		1.40	%		1.23	%
Forfeiture rate		-			-			-

Schedule Of Sharebased Compensation Expense [Table Text Block]

Stock based compensation expense recognized was as follows:

(In thousands of U.S dollars except per share data)	Options						Free of charge share awards						Warrants						Total
	2012		2013		2014		2012		2013		2014		2012		2013		2014		2012		2013		2014
Research and development		419		398		327		649		320		494		-		61		206		1,068		779		1,027
Cost of goods sold		2		1		1		46		19		38		-		-		-		49		20		38
Selling, general and administrative		1,280		903		765		464		211		390		179		116		643		1,923		1,230		1,798

Total stock-based compensation expense		1,701		1,302		1,093		1,160		550		921		179		177		850		3,040		2,029		2,863

Effect on earnings per share
Basic		0.07		0.05		0.03		0.05		0.02		0.03		0.01		0.01		0.02		0.12		0.08		0.08

Diluted		0.07		0.05		0.03		0.05		0.02		0.03		0.01		0.01		0.02		0.12		0.08		0.08

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

The summary of warrants activity is as follows:

	Warrants Outstanding		Weighted Average Exercise Price in U.S dollars [1]		Weighted Average Exercise Price in Euros
Balance at January 1, 2012		900,000	$	6.89	€	4.85
Warrants granted		3,300,000	$	8.63	€	6.61
Warrants reintegrated		100,000	$	6.65	€	4.97
Warrants cancelled		200,000	$	10.20	€	6.57
Balance at December 31, 2012		4,100,000	$	8.12	€	6.18
Warrants granted		200,000	$	6.14	€	4.58
Warrants exercised		50,000	$	6.29	€	4.50
Warrants cancelled		200,000	$	6.29	€	4.50
Balance at December 31, 2013		4,050,000	$	8.14	€	6.21
Warrants granted		298,000	$	14.54	€	10.94
Warrants exercised		445,000	$	6.12	€	4.49
Warrants cancelled		50,000	$	7.02	€	5.44
Balance at December 31, 2014		3,853,000	$	8.86	€	6.76

[1] Historical exchange rate at date of grant

Schedule Of Warrants Activity [Table Text Block]

Exercise prices and intrinsic value for warrants outstanding as of December 31, 2014 were as follows:

	Warrants Outstanding								Warrants Exercisable
Range of exercise prices in euros	Number of shares		Weighted average remaining contractual life		Weighted average exercise price in euros		Weighted average intrinsic value in euros		Number of shares		Weighted average exercise price in euros		Weighted average intrinsic value in euros

0 to 4.58		255,000		1.69		4.17		9.94		255,000		4.17		9.94
5.44 to 6.57		2,200,000		3.20		5.70		8.41		2,200,000		5.70		8.41
6.58 to 8.52		1,100,000		3.20		8.42		5.69		1,100,000		8.42		5.69
8.52 to 10.94		298,000		3.62		10.94		3.17
		3,853,000		3.13		6.78		7.33		3,600,000		6.43		7.68

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

The activity under the option plans is as follows:

	Shares Available for Grant		Options Granted and Outstanding		Weighted Average Exercise Price in U.S dollars[1]		Weighted Average Exercise Price in Euros
Balance at January 1, 2012		275,000		3,140,990	$	14.65	€	11.66
Options authorized		1,000,000		-		-		-
Granted		(550,000)		550,000	$	5.97	€	4.67
Exercised		-		(195,000)	$	2.04	€	2.33
Forfeited		10,000		(223,500)	$	16.88	€	13.69
Balance at December 31, 2012		735,000		3,272,490	$	13.79	€	10.90
Options authorized		600,000		-		-		-
cancelled		(10,000)		-		-		-
Granted		(710,000)		710,000	$	5.97	€	4.36
Forfeited		13,000		(647,500)	$	15.29	€	12.63
Balance at December 31, 2013		628,000		3,334,990	$	11.84	€	9.17
Options authorized		1,700,000		-		-		-
cancelled		(628,000)		-		-		-
Granted		(669,500)		669,500	$	16.30	€	13.15
Exercised		-		(550,750)	$	6.28	€	4.57
Forfeited		-		(955,500)	$	19.19	€	15.00
Balance at December 31, 2014		1,030,500		2,498,240	$	11.45	€	9.02

[1] Historical exchange rate at date of grant

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Exercise prices and intrinsic value for options outstanding as of December 31, 2014 were as follows:

	Stock Options Outstanding								Stock Options Exercisable
Range of exercise prices in euros	Number of shares		Weighted average remaining contractual life		Weighted average exercise price in euros		Weighted average intrinsic value in euros		Number of shares		Weighted average exercise price in euros		Weighted average intrinsic value in euros

0 to 3.28		284,750		7.98		3.02		11.09		84,500		3.06		11.05
4.03 to 5.44		1,069,250		7.72		4.96		9.15		707,750		4.89		9.22
6.40 to 12.02		62,000		0.19		11.42		2.69		62,000		11.42		2.69
12.86 to 16.56		970,990		7.09		13.49		0.88		301,490		14.25		1.19
19.2 to 25.39		111,250		1.59		22.98		-		111,250		22.98		-

		2,498,240		7.05		9.02		8.34		1,266,990		8.90		7.57

Schedule of Share-based Compensation, Activity [Table Text Block]

The activity under the free share award plans is as follows:

	Free of Charge Share Award Available for Grant		Free of Charge Share Award Granted and Outstanding		Weighted Average Fair Value at grant date in U.S dollars[1]		Weighted Average Fair Value at grant date in Euros
Balance at January 1, 2012		26,600		440,650	$	5.81	€	4.36
Options authorized		200,000		-		-		-
Granted		(189,700)		189,700	$	3.07	€	2.38
Exercised		-		(258,150)	$	6.52	€	4.92
Forfeited		21,550		(21,550)	$	5.79	€	4.35
Balance at December 31, 2012		58,450		350,650	$	3.81	€	2.88
Options authorized		200,000		-		-		-
Granted		(192,500)		192,500	$	7.36	€	5.35
Exercised		-		(137,150)	$	4.39	€	3.28
Forfeited		20,600		(38,400)	$	5.10	€	3.72
Balance at December 31, 2013		86,550		367,600	$	5.32	€	3.93
Options authorized		250,000		-		-		-
Granted		(188,300)		188,300	$	16.30	€	13.15
Exercised		-		(150,600)	$	3.07	€	2.38
Forfeited		0		(3,750)	$	7.36	€	5.35
Cancelled		(86,550)
Balance at December 31, 2014		61,700		401,550	$	11.29	€	8.82

[1] Historical exchange rate at date of grant

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Cash and Cash Equivalents (Tables)

12 Months Ended

Dec. 31, 2014

Cash and Cash Equivalents [Abstract]

Schedule of Cash and Cash Equivalents [Table Text Block]

The components of cash and cash equivalents were as follows:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Morgan Stanley	$	0	$	7,784
HSBC		3,657		16,480
Credit Agricole		48		13,529
Commerce Bank		2,898		1,916
Other		33		51
Total cash and cash equivalents	$	6,636	$	39,760

Marketable securities (Tables)

12 Months Ended

Dec. 31, 2014

Investments, Debt and Equity Securities [Abstract]

Trading Securities (and Certain Trading Assets) [Table Text Block]

As of December 31, 2012, 2013 there were no unrealized gains or losses. As of December 31, 2014, an unrealized loss of $0.2 million has been recognized.

(in thousands of U.S dollars)	Fair value						Value at cost						Unrealized Gains (Losses)
	2012		2013		2014		2012		2013		2014		2012		2013		2014
Credit Agricole securities		6,413		401		12,494		6,413		401		12,494		-		-		-
Morgan Stanley securities				-		40,580				-		40,382				-		(198)
Total		6,413		401		53,074		6,413		401		52,876		-		-		(198)

Available-for-sale Securities [Table Text Block]

Gross realized gains on sales of these available-for-sale securities amounted to $6,000, $0 and $963,000 for the years ended December 31, 2012, 2013 and 2014, respectively.

(in thousands of U.S dollars)	Proceeds from sales						Purchase of securities						Gross gains						Gross Losses
	2012		2013		2014		2012		2013		2014		2012		2013		2014		2012		2013		2014
Credit Agricole securities		15,030		7,152		13,678		3,573		1,085		27,752		3		-		243		-		-		-
Morgan Stanley securities				-		-				-		40,523						720		-		-		(416)
HSBC securities		3,216		-		-		-		-		-		3		-		-		-		-		-
Total		18,246		7,152		13,678		3,573		1,085		68,275		6		-		963		-		-		(416)

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Inventory (Tables)

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

The components of inventories were as follows:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Raw materials		918		1,661
Finished goods		1,492		5,068

Inventories, net		2,410		6,729

Prepaid expenses and other current assets (Tables)

12 Months Ended

Dec. 31, 2014

Prepaid Expenses and Other Current Assets [Abstract]

Schedule Of Prepaid Expenses and Other Current Assets [Table Text Block]

The components of prepaid expenses and other current assets were as follows:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Valued-added tax recoverable		689		1,077
Prepaid expenses		1,478		3,225
Advance to suppliers		219		111
Others current assets		95		5
Total Prepaid expenses and other current assets		2,481		4,418

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

The components of property and equipment were as follows:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Land and buildings		-		-
Laboratory equipment		10,985		9,801
Office and computer equipment		3,423		3,289
Furniture, fixtures and fittings		5,067		4,544
Construction in progress		-		-
Total property and equipment		19,475		17,633
Less accumulated depreciation and amortization		(17,084)		(15,857)
Property and equipment, net		2,391		1,776

Goodwill and intangible assets (Tables)

12 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	December 31,
	2013								2014
(In thousands of U.S. dollars)	Gross carrying amount		Accumulated amortization		Impairment		Intangible assets, net		Gross carrying amount		Accumulated amortization		Impairment		Intangible assets, net
Goodwill	$	544		(544)		-		-	$	-		-		-		-
Goodwill Eclat acquisition		18,491		-		-		18,491		18,491		-		-		18,491
Total Goodwill	$	19,035	$	(544)	$	-	$	18,491	$	18,491	$	-	$	-	$	18,491
Intangible asset corresponding to acquired IPR&D of Bloxiverz		35,248		-				35,248		35,248		(11,749)				23,499
Intangible asset corresponding to acquired IPR&D of Vazculep		12,061				(7,170)		4,891		12,061				(7,170)		4,890
Total Intangible assets	$	47,309	$	-	$	(7,170)	$	40,139	$	47,309	$	(11,749)	$	(7,170)	$	28,389

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Total future amortization of intangible assets related to Bloxiverz® and Vazculep™ for the next five years ending December 31 are as follows:

(In thousands of U.S. dollars)	December 31,

2015		12,565
2016		12,565
2017		815
2018		815
2019		815

		27,575

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued expenses comprises of the following:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Accrued compensation		2,440		3,792
Accrued social charges		3,566		1,866
Accrued Interest		521		-
Other		-		9
Total accrued expenses		6,527		5,667

Other current and Long Term liabilities (Tables)

12 Months Ended

Dec. 31, 2014

Other Liabilities Disclosure [Abstract]

Schedule Of Other Current Liabilities [Table Text Block]

Other current liabilities comprise the following:

	December 31,
(In thousands of U.S. dollars)	2013		2014

R&D tax credit financing short term		7,121		5,382
Employee service award provision short term		285		-
Provision for retirement indemnity short term		-		55
Other		72		222
Total Other current liabilities		7,478		5,659

Schedule Of Long Term Liabilities [Table Text Block]

Other long term liabilities are composed of the following:

	December 31,
(In thousands of U.S. dollars)	2013		2014

R&D tax credit financing long term		6,113		-
Provision for retirement indemnity (see note 20)		2,142		2,296
Other		59		37
Total Other long term liabilities		8,314		2,333

Long-term Debt (Tables)

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments [Table Text Block]

Long-term debt comprises:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Oseo ANVAR loans (a)		2,553		1,927
French Ministry of Research (b)		2,033		1,790
Acquisition liability contingent consideration (c)		37,991		70,112
Acquisition liability note (c)		10,405		-
Acquisition liability warrant consideration (c)		10,497		34,542
Deerfield Facility agreement (d)		12,492		-
Deerfield Royalty agreement (d)		4,590		6,837
Broadfin Facility agreement (e)		2,767		-
Broadfin Royalty agreement (e)		2,187		3,259
Total		85,514		118,467
Current portion		19,194		42,332
Long-term portion		66,320		76,135

(a)

(b)

(c)

a $12 million senior, secured six-year note that is guaranteed by the Company and its subsidiaries and secured by the equity interests and assets of Éclat;

two warrants to purchase a total of 3,300,000 American Depositary Shares, each representing one ordinary share of Flamel (“ADSs”); and

The fair value of the warrants was determined by using a Black-Scholes option pricing model with the following assumptions for each of the years indicated:

	2013			2014
Share price		$8.05			$17.13
Risk-free interest rate		1.27	%		1.17	%
Dividend yield		-			-
Expected volatility		50.0	%		56.5	%
Expected term		4.3 years			3.3 years

See also Note 21 – Fair Value of Financial Instruments.

(d)

Consideration received was as follows:

The facility agreement is accounted for at amortized cost using an effective rate of 23%. The Company elected the fair value option for the measurement of the royalty liability.

The facility and royalty agreements are secured by the intellectual property and regulatory rights related to certain Éclat products and certain receivables.

See also Note 21 – Fair Value of Financial Instruments.

(e)

Schedule Of Fair Value Assumptions Of Warrant [Table Text Block]

The fair value of the warrants was determined by using a Black-Scholes option pricing model with the following assumptions for each of the years indicated:

	2013			2014
Share price		$8.05			$17.13
Risk-free interest rate		1.27	%		1.17	%
Dividend yield		-			-
Expected volatility		50.0	%		56.5	%
Expected term		4.3 years			3.3 years

Schedule Of Long Term Debt Maturities [Table Text Block]

(In thousands of U.S. dollars)

2015			45,722
2016			18,163
2017			11,834
2018			13,551
2019			8,758

			98,028

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

+ Details

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation [Table Text Block]

The following is a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations:

	Year ended December 31,
(In thousands, except per share amounts)	2012		2013		2014

Numerator:

Net income (loss) from continuing operations	$	(4,740)	$	(46,511)	$	(88,924)
Net income (loss) from discontinuing operations	$	1,512	$	3,587	$	4,018
Denominator:
Weighted average shares outstanding used for basic earnings (loss) per share		25,135,416		25,450,175		36,214,384
Effect of dilutive securities:
Stock-options and warrants		-		-		-
Weighted average shares outstanding and dilutive securities used for diluted earnings (loss) per share		25,135,416		25,450,175		36,214,384

Earnings (loss) per ordinary share (Basic)
Continuing Operations	$	(0.19)	$	(1.83)	$	(2.45)
Discontinued Operations	$	0.06	$	0.14	$	0.11
Net income (loss)	$	(0.13)	$	(1.69)	$	(2.34)

Earnings (loss) per share (diluted) :
Continuing Operations	$	(0.19)	$	(1.83)	$	(2.45)
Discontinued Operations	$	0.06	$	0.14	$	0.11
Net income (loss)	$	(0.13)	$	(1.69)	$	(2.34)

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2014

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

The components of accumulated other comprehensive income is as follows:

	December 31,
(In thousands of U.S. dollars)	2013		2014

Foreign currency translation		10,815		(7,225)
Unrealized gain (loss) on marketable secuirities				(198)

Total		10,815		(7,423)

Income taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Schedule Of Components Of Income Before Income Tax [Table Text Block]

Income (loss) before income taxes comprises the following:

	Year ended December 31,
(in thousands of U.S. dollars)	2012		2013		2014

France		(15,755)		(3,889)		(392)
United States		6,286		(53,864)		(89,939)
Total	$	(9,469)	$	(57,753)	$	(90,331)

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

A reconciliation of income tax benefit (provision) computed at the French statutory rate (33.33%) and the US statutory rate (40%) to the income tax benefit is as follows:

	Year ended December 31,
(in thousands of U.S. dollars)	2012		2013		2014

Income tax benefit (provision) computed at the statutory rate (US & France)		2,737		22,842		36,106
Deferred Tax Allowance		(5,251)		(1,930)		(10,973)
Business Tax		(59)		(76)		(1,400)
Non Taxable remeasurement of fair value accounting of earn out		7,303		(9,592)		(22,326)
Total	$	4,729	$	11,244	$	1,407

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

Significant components of the Company's deferred taxes consist of the following:

	December 31,
(In thousands of U.S. dollars)	2012		2013		2014

Deferred income tax assets:
Net taxable operating loss carry-forwards (not utilized)		65,657		81,769		66,167
Other deferred income tax assets		3,656		1,898		1,052
Valuation allowance		(64,356)		(69,940)		(57,980)
Net deferred income tax assets		4,957		13,728		9,238
Deferred income tax liabilities		(19,086)		(16,534)		(9,238)
Deferred income taxes, net		(14,130)		(2,806)		-

Schedule Of Income Tax Payments Table [Table Text Block]

The scheduled payments are shown in the following table:

(In thousands of U.S. dollars)	December 31,
2015		5,930
Total current portion		5,930

Employee Retirement plans (Tables)

12 Months Ended

Dec. 31, 2014

Compensation and Retirement Disclosure [Abstract]

Schedule Of Defined Benefit Plan Assumptions [Table Text Block]

The benefit obligation is calculated as the present value of estimated future benefits to be paid, using the following assumptions:

	2012		2013		2014
Average increase of salaries		3%		3%		3%
Discounted interest rate		3%		3.25%		1.49%
Turn over		actuarial standard and average of the last 5 years		actuarial standard and average of the last 5 years		actuarial standard and average of the last 5 years

Age of retirement		60 to 65 years actuarial standard based on age and professional status		60 to 65 years actuarial standard based on age and professional status		60 to 65 years actuarial standard based on age and professional status

Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block]

Changes in the funded status of the benefit plans were as follows:

	December 31,
In thousands of U.S. dollars	2013		2014

Benefit obligations at beginning of year		1,159		2,142
Service cost		1,106		99
Interest cost		36		36
Plan amendments		-		-
Benefits paids		-		(87)
Actuarial loss (gain)		(233)		460
Exchange rate changes		74		(300)
Benefit obligations at end of year		2,142		2,350

Schedule Of Defined Benefit Plan Expected Future Benefit [Table Text Block]

The future expected benefits to be paid over the next five years and for the five years thereafter is as follows:

Future expected payment of benefits:	Year Ending:
In thousands of U.S. dollars
	12/31/2015	55
	12/31/2016	-
	12/31/2017	-
	12/31/2018	-
	12/31/2019	12
	Next 5 Years	150

Fair value of financial instruments (Tables)

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

In thousands of U.S. Dollars	Net Carrying Value as of	Fair Value Measured and Recorded Using			Operational Gain (losses) recognized in	Financial Gain (losses) recognized in
	December 31, 2014	Level 1	Level 2	Level 3	earnings	earnings	Total

Assets
Cash and cash equivalent	39,760	39,760	-	-	-	-	-
Marketable securities	53,074	53,074	-	-	-	547	547
Total					-	547	547
Liabilities
Acquisition liability contingent consideration (a)	70,112	-	-	70,112	(33,445)	-	(33,445)
Acquisition liability note (b)	-	-	-	-	(3,013)	-	(3,013)
Acquisition liability warrant consideration (c)	34,542	-	-	34,542	(24,045)	-	(24,045)
Deerfield Royalty Agreement (d)	6,837			6,837	-	(2,386)	(2,386)
Broadfin Royalty Agreement (e)	3,259			3,259	-	(1,139)	(1,139)
Total					(60,503)	(3,525)	(64,028)

(in thousands)	Net Carrying Value as of	Fair Value Measured and Recorded Using			Operational Gain (losses) recognized in	Financial Gain (losses) recognized in
	December 31, 2013	Level 1	Level 2	Level 3	earnings	earnings	Total
Assets
Cash and cash equivalent	6,636	6,636	-	-	-	-	-
Marketable securities	401	401	-	-	-	-	-

Liabilities
Acquisition liability contingent consideration (a)	37,991	-	-	37,991	(14,768)	-	(14,768)
Acquisition liability note (b)	10,405	-	-	10,405	(5,027)	-	(5,027)
Acquisition liability warrant consideration (c)	10,497	-	-	10,497	(8,340)	-	(8,340)
Deerfield Royalty Agreement (d)	4,590			4,590	-	(1,991)	(1,991)
Broadfin Royalty Agreement (e)	2,187			2,187	-		-
Total					(28,135)	(1,991)	(30,126)

The fair value of the financial instruments in connection with the acquisition of Éclat (see note 2 Business Combinations) are estimated as follows:

(a)

(b)

Acquisition liability Note: the Company uses a probability-weighted discounted cash flow model (see note 16 Long Term Debt).

(c)

(d)

(e)

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]

The following tables provide a reconciliation of fair value for which the Company used Level 3 inputs:

	Acquisition
	Liabilities
Liability recorded upon acquisition	$	(50,927)
Operational gain (loss) recognized in earnings for fiscal year 2012		18,993
Operational gain (loss) recognized in earnings for fiscal year 2013		(28,135)
Payment deferred consideration (Hycet)		841
Payment interest on acquisition liability note		335
Net carrying value at January 1, 2014	$	(58,893)

Operational gain (loss) recognized in earnings for fiscal year 2014		(60,503)
Reimbursment of acquisition liability note		12,000
Payment of interest on acquisition liability note		1,389
Payment of deferred consideration		1,354
Net carrying value at December 31, 2014	$	(104,653)

	Deerfield Royalty		Broadfin Royalty
	Agreement		Agreement
Liability recorded upon execution of Agreeement	$	(2,600)	$	(2,187)
Interest expense recognized in earnings for fiscal year 2013		(1,990)		-
Interest expense recognized in earnings for fiscal year 2014		(2,386)		(1,139)
Payment of Royalty		140		67
Net carrying value at December 31, 2014	$	(6,837)	$	(3,259)

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

Future minimum lease payments under operating leases due for the fiscal years ending December 31, 2014 are as follows:

In thousands of U.S. Dollars	December 31,
2015		841
2016		177
TOTAL		1,018

Industry and geographic information (Tables)

12 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Revenues by geographic location of customers are as follows:

(in thousands of U.S. dollars)	As of December 31,
	2012		2013		2014
Revenues
USA		3,894		3,368		14,302
Europe		3,640		811		473
Total Revenues		7,534		4,179		14,775

Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]

The following is a summary of long-lived assets by geographic location:

(in thousands of U.S. dollars)			As of December 31,
	2012		2013		2014

Long-lived assets:
USA	$	60,260	$	58,868	$	47,077
France	$	31,966	$	2,307	$	1,703
Total long-lived assets	$	92,226	$	61,175	$	48,780

Nature of business and summary of significant accounting policies (Details)	12 Months Ended
	Dec. 31, 2014
Land and Buildings [Member]
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	20 years
Laboratory equipment [Member] \| Minimum [Member]
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	4 years
Laboratory equipment [Member] \| Maximum [Member]
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	8 years
Office and computer equipment [Member]
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	3 years
Furniture, Fixtures and Fittings [Member] \| Minimum [Member]
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	5 years
Furniture, Fixtures and Fittings [Member] \| Maximum [Member]
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	10 years

Nature of business and summary of significant accounting policies (Details Textual)	12 Months Ended
	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)
Nature Of Business And Summary Of Significant Accounting Policies [Line Items]
Allowance for Doubtful Accounts Receivable	$ 127,000	$ 144,000	$ 139,000
Foreign Currency Transaction Gain (Loss), Unrealized	11,600,000
Cash, Cash Equivalents, and Short-term Investments	$ 92,800,000
Historical Revenue Percentage	50
Liquidity Disclosure, Sufficient Cash and Waivers Note	Management believes that the cash and cash equivalents of $92.8 million as of December 2014 are sufficient for the company to continue as a going concern for at least the next twelve months

- Definition

Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.

+ References + Details

Business combinations (Details) $ in Thousands	Dec. 31, 2014 USD ($)
Business Combination, Separately Recognized Transactions [Line Items]
Note	$ 5,625
Warrants	12,065
Deferred consideration	33,237
Total acquisition liabilities	$ 50,927

Business combinations (Details 1) - $ / shares	12 Months Ended
Business combinations (Details 1) - $ / shares	Dec. 31, 2014	Dec. 31, 2013
Business Combination, Separately Recognized Transactions [Line Items]
Share price	$ 17.13	$ 8.05
Risk-free interest rate	1.17%	1.27%
Dividend yield	0.00%	0.00%
Expected volatility	56.50%	50.00%
Expected term	3 years 3 months	4 years 3 months
Warrant [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Share price	$ 7.29
Risk-free interest rate	2.00%
Dividend yield	0.00%
Expected volatility	56.26%
Expected term	6 years

Business combinations (Details Textual) - USD ($)		12 Months Ended
Business combinations (Details Textual) - USD ($)	Mar. 13, 2012	Dec. 31, 2014	Dec. 31, 2013
Business Combination, Separately Recognized Transactions [Line Items]
Contingent Potential Cash Payment			$ 1,000,000
Business Combination Commitment Percentage			100.00%
Fair Value Inputs, Discount Rate		20.00%	20.00%
Finite-lived Intangible Assets Acquired		$ 47,300,000
Future Probability Deferred Compensation Payments	$ 50,927,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net		$ 18,500,000
Fair Value Assumption Probability Percentage		72.00%
Maximum [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Contingent Potential Cash Payment	$ 1,000,000
Income Approach Valuation Technique [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Fair Value Inputs, Discount Rate		20.00%
Senior Secured Six Year Note [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		7.50%
Debt Instrument, Maturity Date		Mar. 24, 2014
Warrant One [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Class Of Warrant Or Right Exercisable	2,200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.44
Warrant Two [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Class Of Warrant Or Right Exercisable	1,100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.00
Eclat Pharmaceuticals [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination Commitment Percentage	20.00%
Eclat Pharmaceuticals [Member] \| Senior Secured Six Year Note [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Debt Instrument, Face Amount	$ 12,000,000
Eclat Pharmaceuticals [Member] \| Two Warrants [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	3,300,000
Hycet [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination Commitment Percentage	100.00%
Fair Value Inputs, Discount Rate		13.00%

License, research and consulting agreements (Details Textual) € in Millions		12 Months Ended
	Oct. 12, 2011 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2009 USD ($)	Dec. 31, 2009 EUR (€)	Dec. 31, 2007 USD ($)	Dec. 31, 2004 USD ($)	Feb. 12, 2014 USD ($)	Oct. 12, 2011 EUR (€)
License, Research And Consulting Agreements [Line Items]
License and Research and Development Revenues		$ 2,800,000	$ 3,000,000	$ 3,300,000
Glaxo Smith Kline [Member]
License, Research And Consulting Agreements [Line Items]
Proceeds from Royalties Received								$ 20,717,000
Coreg Sales [Member]
License, Research And Consulting Agreements [Line Items]
Proceeds from Royalties Received		$ 6,300,000	6,800,000	6,900,000
Merck Serono [Member]
License, Research And Consulting Agreements [Line Items]
Amortization				2,745,000
Up Front Payment							$ 2,700,000
Payment For Exercising The Option					$ 6,500,000	€ 5.0
Maximum Milestone Payments Eligibility					$ 53,000,000	€ 41.0
Accelerated Amortization				1,426,000
Corning France and Corning Incorporated [Member]
License, Research And Consulting Agreements [Line Items]
Proceeds from Royalties Received			111,000	152,000
Corning France and Corning Incorporated [Member] \| Subsequent Event [Member]
License, Research And Consulting Agreements [Line Items]
Research and Product Development Agreement Termination									$ 336,000
Eagle Pharmaceuticals Inc [Member]
License, Research And Consulting Agreements [Line Items]
Research and Development Revenues	$ 345,000		$ 31,600	659,000
Amortization				$ 43,000
Milestone Payments Receivable	$ 1,200,000									€ 0.9

Product sales and services (Details) - Food and Drug Administration [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2014 USD ($)
Sales Revenue, Goods, Gross	$ 15,789
Sales Chargebacks	3,363
Sales Wholesaler Distribution Fees	1,470
Sales Discounts, Goods	326
Sales Returns, Goods	419
Sales Revenue, Goods, Net	10,211
Deferred Sales Gross	11,051
Deferred Sales Chargebacks	132
Deferred Sales Wholesaler Distribution Fees	972
Deferred Sales Cash Discounts And Other	225
Deferred Sales Fees And returns	0
Deferred Revenue	9,722
Deferred Sales Gross Reclassed Against Outstanding Accounts Receivable	(9,420)
Deferred Sales Net Reclassed Against Outstanding Accounts Receivable Chargebacks	(23)
Deferred Sales Net Reclassed Against Outstanding Accounts Receivable Wholesaler distribution fees	(823)
Deferred Sales Net Reclassed Against Outstanding Accounts Receivable Cash discounts and other	(188)
Deferred Sales Net Reclassed Against Outstanding Accounts Receivable Fees and returns	0
Deferred Sales Net Reclassed Against Outstanding Accounts Receivable	(8,386)
Ending Deferred Sales Gross for which Payment has been Collected	1,630
Ending Deferred Sales Gross for which Payment has been Collected Chargebacks	109
Ending Deferred Sales Gross for which Payment has been Collected Wholesaler Distribution Fees	149
Ending Deferred Sales Gross for which Payment has been Collected Cash discounts and other	37
Ending Deferred Sales Gross for which Payment has been Collected Fees And Returns	0
Ending Deferred Sales Net for which Payment has been Collected	$ 1,335

Product sales and services (Details 1)	12 Months Ended
Product sales and services (Details 1)	Dec. 31, 2014 USD ($)
Accounts Receivable Reserves, Balance	$ 144,000
Accounts Receivable Reserves, Ending Balance	127,000
Accounts Receivable Reserves and Liabilities Balance	698,000
Accounts Receivable Reserves and Liabilities Additions	8,667,000
Accounts Receivable Reserves and Liabilities Reductions	(6,656,000)
Accounts Receivable Reserves and Liabilities Ending Balance	2,709,000
Bloxiverz [Member] \| GPO fees [Member]
Liabilities Beginning Balance	6,000
Liabilities Additions	267,000
Liabilities Reductions	(161,000)
Liabilities Balance	112,000
Bloxiverz [Member] \| Sales returns [Member]
Liabilities Beginning Balance	42,000
Liabilities Additions	200,000
Liabilities Reductions	(8,000)
Liabilities Balance	234,000
Bloxiverz [Member] \| Medicaid rebates [Member]
Liabilities Beginning Balance	37,000
Liabilities Additions	16,000
Liabilities Reductions	(29,000)
Liabilities Balance	24,000
Bloxiverz [Member] \| Chargebacks [Member]
Accounts Receivable Reserves, Balance	483,000
Accounts Receivable Reserves, Additions	4,832,000
Accounts Receivable Reserves, Reductions	(4,307,000)
Accounts Receivable Reserves, Ending Balance	1,008,000
Bloxiverz [Member] \| Wholesaler Distribution Fees [Member]
Accounts Receivable Reserves, Balance	102,000
Accounts Receivable Reserves, Additions	2,619,000
Accounts Receivable Reserves, Reductions	(1,642,000)
Accounts Receivable Reserves, Ending Balance	1,079,000
Bloxiverz [Member] \| Cash Discounts And Other [Member]
Accounts Receivable Reserves, Balance	28,000
Accounts Receivable Reserves, Additions	733,000
Accounts Receivable Reserves, Reductions	(508,000)
Accounts Receivable Reserves, Ending Balance	$ 252,000

Product sales and services (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Recognition of Deferred Revenue	$ 2,700	$ 1,100
Sales Revenue Goods and Services Net	11,920	$ 983	$ 560
Bloxiverz [Member]
Sales Revenue, Goods, Net	10,200
Sales Revenue, Goods, Gross	15,800
Deferred Revenue	$ 7,000

R&D expenses (Details) - USD ($) $ in Thousands	12 Months Ended
R&D expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Research And Development Expenses [Line Items]
R&D Expenses	$ 22,800	$ 21,800	$ 21,200
R&D Tax Credit	(5,500)	(5,800)	(6,500)
Grants	0	0	(100)
Total	$ 17,298	$ 15,966	$ 14,558

R&D expenses (Details Textual)	12 Months Ended
R&D expenses (Details Textual)	Dec. 31, 2012 USD ($)
Research And Development Expenses [Line Items]
Revenue from Grants	$ 103,000

Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
Discontinued Operations (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disposal Groups, Including Discontinued Operation Income Statement [Line Items]
Revenues	$ 14,967	$ 18,265	$ 18,570
Income (loss) from operations	(875)	3,667	1,550
Gain (loss) on disposal	5,007	0	0
Interest Expense	(4)	(9)	(11)
Income taxes	(110)	(74)	(27)
Income (loss) from discontinued operations, net of tax	$ 4,018	$ 3,584	$ 1,512

Discontinued Operations (Details 1) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Disposal Groups, Including Discontinued Operation Balance Sheets [Line Items]
Accounts receivable, net	$ 730	$ 0
Inventories	0	1,352
Total major classes of current assets of the discontinued operations	730	1,352
Net Property, plant and equipment	0	15,044
Total major classes of non current assets of the discontinued operations	0	15,044
Total assets of the disposal group classified as held for sale	730	16,396
Current portion of capital lease obligations		69
Accounts payable	168	0
Other current liabilities	0	832
Total major classes of Current Liabilities of the discontinued operations	168	901
Capital lease obligations, less current portion	0	88
Other liabilities	0	7,626
Total major classes of Non-Current Liabilities of assets Held for sale	0	7,714
Total liabilities of the disposal group classified as held for sale	$ 168	$ 8,615

Discontinued Operations (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disposal Groups, Including Discontinued Operation Cash Flows [Line Items]
Capital Expenditures	$ 1,271	$ 872	$ 766
Depreciation and Amortization	1,709	1,751	1,910
Operating and Investing non-cash elements	$ (740)	$ (676)	$ (975)

Discontinued Operations (Details 3) $ in Thousands	12 Months Ended
Discontinued Operations (Details 3) $ in Thousands	Dec. 31, 2014 USD ($)
Supply And Services Of Products [Line Items]
First Year	$ 4,250
Second Year	4,250
Third Year	4,250
Fourth Year	4,860
Fifth Year	$ 4,860

Discontinued Operations (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
Discontinued Operations (Details Textual) - USD ($)	Jul. 31, 2006	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2004
Discontinued Operations [Line Items]
Other Revenue, Net		$ 73,000	$ 170,000	$ 250,000
License and Research Revenue		2,782,000	3,026,000	6,724,000
Supply Agreement, Total Funding	$ 8,100,000
Minimum Amount On Supply And Services Of Products		22,500,000
Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax		5,007,000	0	0
Stock Issued During Period, Value, Acquisitions		$ 13,050,000
Recipharm AB [Member]
Discontinued Operations [Line Items]
Percentage Of Margin On Costs Incurred On Services		20.00%
Recipharm AB [Member] \| Equity Securities [Member]
Discontinued Operations [Line Items]
Stock Issued During Period, Value, Acquisitions		$ 13,000,000
Equity Method Investment, Ownership Percentage		2.30%
Pessac Business [Member]
Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses		$ 13,200,000
Contribution For Potential Employee Obligations		700,000
Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax		5,000,000
Buildings And Fixtures [Member]
Discontinued Operations [Line Items]
Payments to Acquire Productive Assets		8,188,000
Equipment And Asscociated Costs [Member]
Discontinued Operations [Line Items]
Payments to Acquire Productive Assets		11,138,000
Glaxo Smith Kline [Member]
Discontinued Operations [Line Items]
Proceeds From Production Facilities					$ 20,717,000
Undisclosed Partners [Member]
Discontinued Operations [Line Items]
License and Research Revenue		2,000,000	3,500,000	2,600,000
Coreg Sales [Member]
Discontinued Operations [Line Items]
Proceeds From Production Facilities		6,300,000	6,800,000	6,900,000
Other Revenue, Net		$ 6,700,000	$ 8,000,000	$ 9,100,000

Stock based compensation (Details)	12 Months Ended
Stock based compensation (Details)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average expected life (years)	4 years 3 months 4 days	5 years 5 months 5 days	5 years 8 months 12 days
Expected volatility rate	61.00%	61.00%	62.50%
Expected dividend yield	0.00%	0.00%	0.00%
Risk-free interest rate	1.23%	1.40%	0.95%
Forfeiture rate	0.00%	0.00%	0.00%

Stock based compensation (Details 1) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 2,863	$ 2,029	$ 3,040
Effect on earnings per share
Basic	$ 0.08	$ 0.08	$ 0.12
Diluted	$ 0.08	$ 0.08	$ 0.12
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 1,093	$ 1,302	$ 1,701
Effect on earnings per share
Basic	$ 0.03	$ 0.05	$ 0.07
Diluted	$ 0.03	$ 0.05	$ 0.07
Free Of Charge Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 921	$ 550	$ 1,160
Effect on earnings per share
Basic	$ 0.03	$ 0.02	$ 0.05
Diluted	$ 0.03	$ 0.02	$ 0.05
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 850	$ 177	$ 179
Effect on earnings per share
Basic	$ 0.02	$ 0.01	$ 0.01
Diluted	$ 0.02	$ 0.01	$ 0.01
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 1,027	$ 779	$ 1,068
Research and Development Expense [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	327	398	419
Research and Development Expense [Member] \| Free Of Charge Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	494	320	649
Research and Development Expense [Member] \| Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	206	61	0
Cost Of Goods Sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	38	20	49
Cost Of Goods Sold [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	1	1	2
Cost Of Goods Sold [Member] \| Free Of Charge Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	38	19	46
Cost Of Goods Sold [Member] \| Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	0	0	0
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	1,798	1,230	1,923
Selling, General and Administrative Expenses [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	765	903	1,280
Selling, General and Administrative Expenses [Member] \| Free Of Charge Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	390	211	464
Selling, General and Administrative Expenses [Member] \| Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 643	$ 116	$ 179

Stock based compensation (Details 2) - Warrant [Member]

12 Months Ended

Dec. 31, 2014

€ / shares

Dec. 31, 2014

$ / shares

Dec. 31, 2013

€ / shares

Dec. 31, 2013

$ / shares

Dec. 31, 2012

€ / shares

Dec. 31, 2012

$ / shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Balance, Warrants Outstanding

4,050,000

4,100,000

900,000

Warrants granted

298,000

200,000

3,300,000

Warrants reintegrated

100,000

Warrants exercised

445,000

50,000

Warrants cancelled

50,000

200,000

Balance, Warrants Outstanding

3,853,000

4,050,000

4,100,000

Balance, Weighted Average Exercise Price | (per share)

€ 6.21

$ 8.14

^[1]

€ 6.18

$ 8.12

^[1]

€ 4.85

$ 6.89

^[1]

Warrants granted, Weighted Average Exercise Price | (per share)

10.94

14.54

^[1]

4.58

6.14

^[1]

6.61

8.63

^[1]

Warrants reintegrated, Weighted Average Exercise Price | (per share)

4.97

6.65

^[1]

Warrants cancelled, Weighted Average Exercise Price | (per share)

5.44

7.02

^[1]

4.50

6.29

^[1]

6.57

10.20

^[1]

Warrants exercised, Weighted Average Exercise Price | (per share)

4.49

6.12

^[1]

4.50

6.29

^[1]

Balance, Weighted Average Exercise Price | (per share)

€ 6.76

$ 8.86

^[1]

€ 6.21

$ 8.14

^[1]

€ 6.18

$ 8.12

^[1]

[1]	Historical exchange rate at date of grant

Stock based compensation (Details 3)

12 Months Ended

Dec. 31, 2014

€ / shares

Dec. 31, 2014

$ / shares

Dec. 31, 2013

€ / shares

Dec. 31, 2013

$ / shares

Dec. 31, 2012

€ / shares

Dec. 31, 2012

$ / shares

Dec. 31, 2011

€ / shares

Dec. 31, 2011

$ / shares

Warrant One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Outstanding, Number of shares | shares

255,000

Warrants Outstanding, Weighted average remaining contractual life (in years)

1 year 8 months 8 days

Warrants Outstanding, Weighted Average Exercise Price

€ 4.17

Warrants Outstanding, Weighted Average Intrinsic Value

€ 9.94

Warrants Exercisable, Number of shares | shares

255,000

Warrants Exercisable, Weighted Average Exercise Price

€ 4.17

Warrants Exercisable, Weighted Average Intrinsic Value

9.94

Warrant One [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Exercise Price

4.58

Warrant One [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Exercise Price

€ 0

Warrant Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Outstanding, Number of shares | shares

2,200,000

Warrants Outstanding, Weighted average remaining contractual life (in years)

3 years 2 months 12 days

Warrants Outstanding, Weighted Average Exercise Price

€ 5.70

Warrants Outstanding, Weighted Average Intrinsic Value

€ 8.41

Warrants Exercisable, Number of shares | shares

2,200,000

Warrants Exercisable, Weighted Average Exercise Price

€ 5.70

Warrants Exercisable, Weighted Average Intrinsic Value

8.41

Warrant Two [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Exercise Price

6.57

Warrant Two [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Exercise Price

€ 5.44

Warrant Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Outstanding, Number of shares | shares

1,100,000

Warrants Outstanding, Weighted average remaining contractual life (in years)

3 years 2 months 12 days

Warrants Outstanding, Weighted Average Exercise Price

€ 8.42

Warrants Outstanding, Weighted Average Intrinsic Value

€ 5.69

Warrants Exercisable, Number of shares | shares

1,100,000

Warrants Exercisable, Weighted Average Exercise Price

€ 8.42

Warrants Exercisable, Weighted Average Intrinsic Value

5.69

Warrant Three [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Exercise Price

8.52

Warrant Three [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Exercise Price

€ 6.58

Warrant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Outstanding, Number of shares | shares

3,853,000

4,050,000

4,100,000

900,000

Warrants Outstanding, Weighted average remaining contractual life (in years)

3 years 1 month 17 days

Warrants Outstanding, Weighted Average Exercise Price | (per share)

€ 6.76

$ 8.86

^[1]

€ 6.21

$ 8.14

^[1]

€ 6.18

$ 8.12

^[1]

€ 4.85

$ 6.89

^[1]

Warrants Outstanding, Weighted Average Intrinsic Value

€ 7.33

Warrants Exercisable, Number of shares | shares

3,600,000

Warrants Exercisable, Weighted Average Exercise Price

€ 6.43

Warrants Exercisable, Weighted Average Intrinsic Value

€ 7.68

Warrent Four [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Outstanding, Number of shares | shares

298,000

Warrants Outstanding, Weighted average remaining contractual life (in years)

3 years 7 months 13 days

Warrants Outstanding, Weighted Average Exercise Price

€ 10.94

Warrants Outstanding, Weighted Average Intrinsic Value

3.17

Warrent Four [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Exercise Price

10.94

Warrent Four [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants Exercise Price

€ 8.52

[1]	Historical exchange rate at date of grant

Stock based compensation (Details 4) - Employee Stock Option [Member]

12 Months Ended

Dec. 31, 2014

€ / shares

Dec. 31, 2014

$ / shares

Dec. 31, 2013

€ / shares

Dec. 31, 2013

$ / shares

Dec. 31, 2012

€ / shares

Dec. 31, 2012

$ / shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Balance, Free of Charge Share Award Available for Grant -Beginning Balance

628,000

735,000

275,000

Options authorized, Share Available for Grant

1,700,000

600,000

1,000,000

Cancelled, Share Available for Grant

(628,000)

(10,000)

Granted, Shares Available For Grant

(669,500)

(710,000)

(550,000)

Exercised, Shares Available For Grant

Forfeited, Shares Available For Grant

13,000

10,000

Balance, Free of Charge Share Award Available for Grant - Ending Balance

1,030,500

628,000

735,000

Balance, Free of Charge Share Award Granted and Outstanding -Beginning Balance

3,334,990

3,272,490

3,140,990

Options authorized, Options Granted and Outstanding

Cancelled, Options Granted and Outstanding

Granted, Options Granted and Outstanding

669,500

710,000

550,000

Exercised, Options Granted and Outstanding

(550,750)

(195,000)

Forfeited, Options Granted and Outstanding

(955,500)

(647,500)

(223,500)

Balance, Free of Charge Share Award Granted and Outstanding - Ending Balance

2,498,240

3,334,990

3,272,490

Balance,Weighted Average Fair Value - Beginning Balance | (per share)

€ 9.17

$ 11.84

^[1]

€ 10.90

$ 13.79

^[1]

€ 11.66

$ 14.65

^[1]

Options Authorized, Weighted Average Exercise Price | (per share)

^[1]

Cancelled, Weighted Average Exercise Price | (per share)

^[1]

Granted, Weighted Average Exercise Price | (per share)

13.15

16.30

^[1]

4.36

5.97

^[1]

4.67

5.97

^[1]

Exercised, Weighted Average Exercise Price | (per share)

4.57

6.28

^[1]

2.33

2.04

^[1]

Forfeited, Weighted Average Exercise Price | (per share)

15.00

19.19

^[1]

12.63

15.29

^[1]

13.69

16.88

^[1]

Balance, Weighted Average Fair Value - Ending Balance | (per share)

€ 9.02

$ 11.45

^[1]

€ 9.17

$ 11.84

^[1]

€ 10.90

$ 13.79

^[1]

[1]	Historical exchange rate at date of grant

Stock based compensation (Details 5)	12 Months Ended
Stock based compensation (Details 5)	Dec. 31, 2014 € / shares shares
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Number of shares \| shares	284,750
Stock Options Outstanding, Weighted average remaining contractual life (in Years)	7 years 11 months 23 days
Stock Options Outstanding, Weighted average exercise price in euros	€ 3.02
Stock Options Outstanding, Weighted average intrinsic value in euros	€ 11.09
Stock Options Exercisable, Number of shares \| shares	84,500
Stock Options Exercisable, Weighted average exercise price in euros	€ 3.06
Stock Options Exercisable, Weighted average intrinsic value in euros	11.05
Stock Option One [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices in euros	0
Stock Option One [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices in euros	€ 3.28
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Number of shares \| shares	1,069,250
Stock Options Outstanding, Weighted average remaining contractual life (in Years)	7 years 8 months 19 days
Stock Options Outstanding, Weighted average exercise price in euros	€ 4.96
Stock Options Outstanding, Weighted average intrinsic value in euros	€ 9.15
Stock Options Exercisable, Number of shares \| shares	707,750
Stock Options Exercisable, Weighted average exercise price in euros	€ 4.89
Stock Options Exercisable, Weighted average intrinsic value in euros	9.22
Stock Option Two [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices in euros	4.03
Stock Option Two [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices in euros	€ 5.44
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Number of shares \| shares	62,000
Stock Options Outstanding, Weighted average remaining contractual life (in Years)	2 months 8 days
Stock Options Outstanding, Weighted average exercise price in euros	€ 11.42
Stock Options Outstanding, Weighted average intrinsic value in euros	€ 2.69
Stock Options Exercisable, Number of shares \| shares	62,000
Stock Options Exercisable, Weighted average exercise price in euros	€ 11.42
Stock Options Exercisable, Weighted average intrinsic value in euros	2.69
Stock Option Three [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices in euros	6.40
Stock Option Three [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices in euros	€ 12.02
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Number of shares \| shares	970,990
Stock Options Outstanding, Weighted average remaining contractual life (in Years)	7 years 1 month 2 days
Stock Options Outstanding, Weighted average exercise price in euros	€ 13.49
Stock Options Outstanding, Weighted average intrinsic value in euros	€ 0.88
Stock Options Exercisable, Number of shares \| shares	301,490
Stock Options Exercisable, Weighted average exercise price in euros	€ 14.25
Stock Options Exercisable, Weighted average intrinsic value in euros	1.19
Stock Option Four [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices in euros	12.86
Stock Option Four [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices in euros	€ 16.56
Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Number of shares \| shares	111,250
Stock Options Outstanding, Weighted average remaining contractual life (in Years)	1 year 7 months 2 days
Stock Options Outstanding, Weighted average exercise price in euros	€ 22.98
Stock Options Outstanding, Weighted average intrinsic value in euros	€ 0
Stock Options Exercisable, Number of shares \| shares	111,250
Stock Options Exercisable, Weighted average exercise price in euros	€ 22.98
Stock Options Exercisable, Weighted average intrinsic value in euros	0
Stock Option Five [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices in euros	19.2
Stock Option Five [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices in euros	€ 25.39
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Number of shares \| shares	2,498,240
Stock Options Outstanding, Weighted average remaining contractual life (in Years)	7 years 18 days
Stock Options Outstanding, Weighted average exercise price in euros	€ 9.02
Stock Options Outstanding, Weighted average intrinsic value in euros	€ 8.34
Stock Options Exercisable, Number of shares \| shares	1,266,990
Stock Options Exercisable, Weighted average exercise price in euros	€ 8.90
Stock Options Exercisable, Weighted average intrinsic value in euros	€ 7.57

Stock based compensation (Details 6) - Free Share Award [Member]

12 Months Ended

Dec. 31, 2014

€ / shares

Dec. 31, 2014

$ / shares

Dec. 31, 2013

€ / shares

Dec. 31, 2013

$ / shares

Dec. 31, 2012

€ / shares

Dec. 31, 2012

$ / shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Balance, Free of Charge Share Award Available for Grant -Beginning Balance

86,550

58,450

26,600

Options authorized, Free of Charge Share Award Available for Grant

250,000

200,000

Granted, Free of Charge Share Award Available for Grant

(188,300)

(192,500)

(189,700)

Exercised, Free of Charge Share Award Available for Grant

Forfeited, Free of Charge Share Award Available for Grant

20,600

21,550

Cancelled, Free of Charge Share Award Available for Grant

(86,550)

Balance, Free of Charge Share Award Available for Grant - Ending Balance

61,700

86,550

58,450

Balance, Free of Charge Share Award Granted and Outstanding -Beginning Balance

367,600

350,650

440,650

Options authorized Free of Charge Share Award Granted and Outstanding

Granted Free of Charge Share Award Granted and Outstanding

188,300

192,500

189,700

Exercised, Options Granted and Outstanding

(150,600)

(137,150)

(258,150)

Forfeited, Options Granted and Outstanding

(3,750)

(38,400)

(21,550)

Balance, Free of Charge Share Award Granted and Outstanding - Ending Balance

401,550

367,600

350,650

Balance,Weighted Average Fair Value - Beginning Balance | (per share)

€ 3.93

$ 5.32

^[1]

€ 2.88

$ 3.81

^[1]

€ 4.36

$ 5.81

Options authorized Weighted Average Fair Value at grant date | (per share)

^[2]

Granted Weighted Average Fair Value at grant date | (per share)

13.15

16.30

^[2]

5.35

7.36

^[2]

2.38

3.07

^[2]

Exercised Weighted Average Fair Value at grant date | (per share)

2.38

3.07

^[2]

3.28

4.39

^[2]

4.92

6.52

^[2]

Forfeited Weighted Average Fair Value at grant date | (per share)

5.35

7.36

^[2]

3.72

5.10

^[2]

4.35

5.79

^[2]

Balance, Weighted Average Fair Value - Ending Balance | (per share)

€ 8.82

$ 11.29

^[1]

€ 3.93

$ 5.32

^[1]

€ 2.88

$ 3.81

^[1]

[1]	Historical exchange rate at date of grant
[2]	Historical exchange rate at date of grant

Stock based compensation (Details Textual)	12 Months Ended
Stock based compensation (Details Textual)	Dec. 31, 2014 USD ($) shares	Dec. 31, 2014 EUR (€) shares	Dec. 31, 2013 USD ($) shares	Dec. 31, 2013 EUR (€) shares	Dec. 31, 2012 USD ($) shares	Dec. 31, 2012 EUR (€) shares	Dec. 31, 2014 EUR (€)	Dec. 31, 2013 EUR (€)	Dec. 31, 2012 EUR (€)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized \| $	$ 10,899,000		$ 4,090,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	2 years 1 month 24 days	2 years 1 month 24 days	2 years 1 month 17 days	2 years 1 month 17 days
Fair Value Of Warrants Vested	$ 300,000	€ 225,500	$ 0	€ 0	$ 348,000	€ 271,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value	3,789,000	2,864,000			973,000	735,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	1,265,000	€ 952,000	$ 1,327,000	€ 999,000	$ 1,088,000	€ 846,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	18,555,000						€ 13,964,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 10,606,000						7,981,000
Warrants Exercised \| shares	445,000	445,000	50,000	50,000	0	0
Warrants Outstanding Intrinsic Value	$ 37,070,000						28,237,000
Free Share Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 4,533,000		$ 1,954,000		$ 1,336,000		€ 3,544,000	€ 1,446,000	€ 1,009,000

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 39,760	$ 6,636	$ 2,742	$ 3,456
Morgan Stanley [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	7,784	0
HSBC [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	16,480	3,657
Credit Agricole [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	13,529	48
Commerce Bank [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	1,916	2,898
Other [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 51	$ 33

Marketable securities (Details) - USD ($) $ in Thousands	12 Months Ended
Marketable securities (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Marketable Securities [Line Items]
Fair value	$ 53,074	$ 401	$ 6,413
Value at cost	53,074	401	6,413
Unrealized Gains (Losses)	(198)	0	0
Credit Agricole securities [Member]
Marketable Securities [Line Items]
Fair value	12,494	401	6,413
Value at cost	12,494	401	6,413
Unrealized Gains (Losses)	0	0	$ 0
Morgan Stanley securities [Member]
Marketable Securities [Line Items]
Fair value	40,580	0
Value at cost	40,382	0
Unrealized Gains (Losses)	$ (198)	$ 0

Marketable securities (Details 1) - USD ($) $ in Thousands	12 Months Ended
Marketable securities (Details 1) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Marketable Securities [Line Items]
Proceeds from sales	$ 13,678	$ 7,152	$ 18,246
Purchase of securities	68,275	1,085	3,567
Gross gains	963	0	6
Gross Losses	(416)	0	0
Credit Agricole securities [Member]
Marketable Securities [Line Items]
Proceeds from sales	13,678	7,152	15,030
Purchase of securities	27,752	1,085	3,573
Gross gains	243	0	3
Gross Losses	0	0	0
Morgan Stanley securities [Member]
Marketable Securities [Line Items]
Proceeds from sales	0	0
Purchase of securities	40,523	0
Gross gains	720
Gross Losses	(416)	0	0
HSBC securities [Member]
Marketable Securities [Line Items]
Proceeds from sales	0	0	3,216
Purchase of securities	0	0	0
Gross gains	0	0	3
Gross Losses	$ 0	$ 0	$ 0

Marketable securities (Details Textual) - USD ($)	12 Months Ended
Marketable securities (Details Textual) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Marketable Securities [Line Items]
Marketable securities	$ 53,074,000	$ 401,000	$ 6,413,000
Unrealized Loss on Securities	200,000
Marketable Securities, Realized Gain (Loss)	$ 963,000	$ 0	$ 6,000

Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Raw materials	$ 1,661	$ 918
Finished goods	5,068	1,492
Inventories, net	$ 6,729	$ 2,410

Prepaid expenses and other current assets (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Prepaid Expenses And Other Current Assets [Line Items]
Valued-added tax recoverable	$ 1,077	$ 689
Prepaid expenses	3,225	1,478
Advance to suppliers	111	219
Others current assets	5	95
Total Prepaid expenses and other current assets	$ 4,418	$ 2,481

Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 17,633	$ 19,475
Less accumulated depreciation and amortization	(15,857)	(17,084)
Property and equipment, net	1,776	2,391
Land and buildings [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	0	0
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	9,801	10,985
Office and computer equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	3,289	3,423
Furniture, fixtures and fittings [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	4,544	5,067
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 0	$ 0

Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Depreciation of property and equipment	$ 14,141	$ 3,062	$ 3,183
Property, Plant and Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation of property and equipment	$ 700	$ 800	$ 800

Goodwill and intangible assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Goodwill, Gross	$ 18,491	$ 19,035
Accumulated Amortization, Goodwill	0	(544)
Impairment, Goodwill	0	0
Intangible Assets, Net (Including Goodwill)	18,491	18,491
Gross carrying amount	47,309	47,309
Accumulated amortization	(11,749)	0
Impairment	(7,170)	(7,170)
Intangible assets, net	28,389	40,139
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill, Gross	0	544
Accumulated Amortization, Goodwill	0	(544)
Impairment, Goodwill	0	0
Intangible Assets, Net (Including Goodwill)	0	0
Goodwill Eclat Acquisition [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill, Gross	18,491	18,491
Accumulated Amortization, Goodwill	0	0
Impairment, Goodwill	0	0
Intangible Assets, Net (Including Goodwill)	18,491	18,491
Research and Development In Process [Member] \| Vazculep [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	12,061	12,061
Impairment	(7,170)	(7,170)
Intangible assets, net	4,890	4,891
Research and Development In Process [Member] \| Bloxiverz [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	35,248	35,248
Accumulated amortization	(11,749)	0
Intangible assets, net	$ 23,499	$ 35,248

Goodwill and intangible assets (Details 1) $ in Thousands	Dec. 31, 2014 USD ($)
Finite-Lived Intangible Assets [Line Items]
2015	$ 12,565
2016	12,565
2017	815
2018	815
2019	815
Finite-Lived Intangible Assets, Net	$ 27,575

Goodwill and intangible assets (Details Textual) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets (Excluding Goodwill), Total			$ 0	$ 0	$ 7,170
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		3 years
In Process Research and Development [Member] \| Subsequent Event [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	6 years

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses [Line Items]
Accrued compensation	$ 3,792	$ 2,440
Accrued social charges	1,866	3,566
Accrued Interest	0	521
Other	9	0
Total accrued expenses	$ 5,667	$ 6,527

Other current and Long Term liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Other Current And Long Term Liabilities [Line Items]
R&D tax credit financing short term	$ 5,382	$ 7,121
Employee service award provision short term	0	285
Provision for retirement indemnity short term	55	0
Other	222	72
Total Other current liabilities	$ 5,659	$ 7,478

Other current and Long Term liabilities (Details 1) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Other Current And Long Term Liabilities [Line Items]
R&D credit tax financing long term	$ 0	$ 6,113
Provision for retirement indemnity (see note 20)	2,296	2,142
Other	37	59
Total Other long term liabilities	$ 2,333	$ 8,314

Other current and Long Term liabilities (Details Textual)	12 Months Ended
	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2012 EUR (€)
Other Current And Long Term Liabilities [Line Items]
Other current liabilities	$ 5,659,000	$ 7,478,000
Other long-term liabilities	2,333,000	8,314,000
Research and Development Tax Credit	$ 5,500,000	5,800,000	$ 6,500,000
Oseo Anvar [Member]
Other Current And Long Term Liabilities [Line Items]
Other current liabilities		7,121,000
Other long-term liabilities		6,113,000
Provision For Service Award Short Term		285,000
Proceeds From Advances			$ 5,848,000	€ 4,432,000
Interest Rate On Advance			Euro Interbank Offered Rate (EURIBOR) plus 0.9%.	Euro Interbank Offered Rate (EURIBOR) plus 0.9%.
Service Award Provision Period	The Service award provision is accrued over the respective service period (5, 10, 15 and 20 years).
Research and Development Tax Credit		13,234,000
Total Funding	$ 5,382,000	$ 13,234,000

Long-term Debt (Details) - USD ($)
$ in Thousands

Dec. 31, 2014

Dec. 31, 2013

Schedule of Capitalization, Long-term Debt [Line Items]

Total

$ 118,467

$ 85,514

Current portion

42,332

19,194

Long-term portion

76,135

66,320

Oseo ANVAR loans [Member]

Schedule of Capitalization, Long-term Debt [Line Items]

Total

^[1]

1,927

2,553

French Ministry Of Research [Member]

Schedule of Capitalization, Long-term Debt [Line Items]

Total

^[2]

1,790

2,033

Acquisition liability contingent consideration [Member]

Schedule of Capitalization, Long-term Debt [Line Items]

Total

^[3]

70,112

37,991

Acquisition liability note [Member]

Schedule of Capitalization, Long-term Debt [Line Items]

Total

^[3]

10,405

Acquisition liability warrant consideration [Member]

Schedule of Capitalization, Long-term Debt [Line Items]

Total

^[3]

34,542

10,497

Deerfield Facility agreement [Member]

Schedule of Capitalization, Long-term Debt [Line Items]

Total

^[4]

12,492

Deerfield Royalty agreement [Member]

Schedule of Capitalization, Long-term Debt [Line Items]

Total

^[4]

6,837

4,590

Broadfin Facility agreement [Member]

Schedule of Capitalization, Long-term Debt [Line Items]

Total

^[5]

2,767

Broadfin Royalty agreement [Member]

Schedule of Capitalization, Long-term Debt [Line Items]

Total

^[5]

$ 3,259

$ 2,187

[1]	OSEO Anvar is an agency of the French government that provides financing to French companies for R&D. At December 31, 2013 and 2014, the Company had outstanding loans from Anvar of $2,553,000 and $1,927,000, respectively for various programs. These loans do not bear interest and are repayable only in the event the research project is technically or commercially successful. Repayment is scheduled to occur from 2014 through 2019.
[2]	In 2002, the Company received a loan of $464,000 from the French Ministry of Research on a research project (the “Proteozome” project) related to the development of new Medusa applications. Pursuant to the agreement, the Company is granted a loan equal to 50% of the total expenses incurred on this project over a three-year period beginning on January 2, 2002. The remainder of the advance of $1,707,000 was received in 2005. This loan is due for repayment in 2015. The loan is non-interest bearing and is repayable only in the event the research project is technically or commercially successful. The company has not received official acceptance notice of commercial and technical success.
[3]	The Acquisition liability relates to the acquisition by the Company through its wholly owned subsidiary Flamel US Holdings, Inc., or Flamel US, all of the membership interests of Éclat Pharmaceuticals, LLC (see note 2 Business combinations). In exchange for all of the issued and outstanding membership interests of Éclat Pharmaceuticals, Flamel US provided consideration consisting of: ⋅ a $12 million senior, secured six-year note that is guaranteed by the Company and its subsidiaries and secured by the equity interests and assets of Éclat; ⋅ two warrants to purchase a total of 3,300,000 American Depositary Shares, each representing one ordinary share of Flamel (“ADSs”); and ⋅ a commitment to make earn out payments of 20% of any gross profit generated by certain Éclat Pharmaceuticals launch products and to pay 100% of any gross profit generated by Hycet® up to a maximum of $1 million. The Purchase Agreement also contains certain representations and warranties, covenants, indemnification and other customary provisions.
[4]	On February 4, 2013 the Company concluded a $15 million debt financing transaction (Facility Agreement) with Deerfield Management, a current shareholder. Subject to certain limitations, the Company may use the funds for working capital, including continued investment in its R&D projects.
[5]	On December 3, 2013 the Company concluded with Broadfin Healthcare Master Fund, a current shareholder, a $15 million debt financing transaction (Facility Agreement) divided in 3 tranche of $5 million each, Under the terms of the Facility, upon closing Broadfin made an initial loan of $5.0 million and the Company was entitled to request, at any time prior to August 15, 2014, up to two additional loans in the amount of $5.0 million each, with funding subject to certain specified conditions. Subject to certain limitations, the Company was permitted to use the funds for working capital, including continued investment in its R&D projects.

Long-term Debt (Details 1) - $ / shares	12 Months Ended
Long-term Debt (Details 1) - $ / shares	Dec. 31, 2014	Dec. 31, 2013
Schedule of Capitalization, Long-term Debt [Line Items]
Share price	$ 17.13	$ 8.05
Risk-free interest rate	1.17%	1.27%
Dividend yield	0.00%	0.00%
Expected volatility	56.50%	50.00%
Expected term	3 years 3 months	4 years 3 months

Long-term Debt (Details 2) $ in Thousands	Dec. 31, 2014 USD ($)
Schedule of Capitalization, Long-term Debt [Line Items]
2015	$ 45,722
2016	18,163
2017	11,834
2018	13,551
2019	8,758
Long Term Debt	$ 98,028

Long-term Debt (Details Textual) - USD ($)			12 Months Ended
Long-term Debt (Details Textual) - USD ($)	Dec. 03, 2013	Feb. 04, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2002	Dec. 31, 2005
Schedule of Capitalization, Long-term Debt [Line Items]
Proceeds from loans or conditional grants			$ 0	$ 19,333,000	$ 6,668,000
Secured Debt			$ 12,000,000
Percentage Of Earn Out Payment			20.00%
Percentage Of Commitment			100.00%
Business Acquisition, Commitment Amount			$ 1,000,000
Debt Financing Facility Agreement Amount	$ 5,000,000
Fair Value Inputs, Discount Rate			20.00%	20.00%
Fair Value Inputs, Cap Rate				100.00%
Interest Expense, Total			$ 5,747,000	$ 2,602,000	$ 118,000
American Depository Shares [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			3,300,000
Oseo Anvar [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Proceeds from loans or conditional grants			$ 1,927,000	$ 2,553,000
French Ministry Of Research [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Proceeds from loans or conditional grants						$ 464,000
Long Term Debt Advance, Remaining amount							$ 1,707,000
Facility Agreement [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt Financing Facility Agreement Amount	$ 15,000,000	$ 15,000,000
Long Term Debt, Repayment Of Principal In First Year		10.00%
Long Term Debt, Repayment Of Principal In Second Year		20.00%
Long Term Debt, Repayment Of Principal In Third Year	100.00%	30.00%
Long Term Debt, Repayment Of Principal In Fourth Year		40.00%
Fund Raised From Debt Financing Facility	$ 5,000,000	$ 12,400,000	$ 2,800,000
Premium On Reimbursement		2,600,000
Debt Repayment Term	Jan. 01, 2017
Initial Loan Amount	$ 5,000,000
Additional Loan Amount	5,000,000
Debt Financing Nominal Value	5,000,000
Royalty Agreement [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Fund Raised From Debt Financing Facility	$ 2,200,000	$ 2,600,000
Long Term Debt Repayment Percentage	0.834%	1.75%
Amortized Cost Effective Rate	41.00%		23.00%
Debt Repayment Term	Dec. 31, 2024		Dec. 31, 2024
Deerfield Facility agreement [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt Instrument, Maturity Date		Mar. 24, 2014
Broadfin Healthcare Master Fund Ltd [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt Instrument, Maturity Date	Mar. 24, 2014

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Numerator:
Net income (loss) from continuing operations	$ (88,924)	$ (46,509)	$ (4,740)
Net income (loss) from discontinuing operations	$ 4,018	$ 3,584	$ 1,512
Denominator:
Weighted average shares outstanding used for basic earnings (loss) per share (in shares)	36,214	25,450	25,135
Effect of dilutive securities:
Stock-options and warrants	$ 0	$ 0	$ 0
Weighted average shares outstanding and dilutive securities used for diluted earnings (loss) per share (in shares)	36,214	25,450	25,135
Earnings (loss) per ordinary share (Basic)
Continuing Operations	$ (2.45)	$ (1.83)	$ (0.19)
Discontinued Operations	0.11	0.14	0.06
Net income (loss)	(2.34)	(1.69)	(0.13)
Earnings (loss) per share (diluted) :
Continuing Operations	(2.45)	(1.83)	(0.19)
Discontinued Operations	0.11	0.14	0.06
Net income (loss)	$ (2.34)	$ (1.69)	$ (0.13)

Earnings Per Share (Details Textual)	12 Months Ended
Earnings Per Share (Details Textual)	Dec. 31, 2014 $ / shares shares
Earnings Per Share [Line Items]
Options Purchase Price \| $ / shares	$ 9.87
Equity Option [Member]
Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount \| shares	6,396,240

Shareholders' Equity (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Foreign currency translation	$ (7,225)	$ 10,815
Unrealized gain (loss) on marketable secuirities	(198)
Total	$ (7,423)	$ 10,815

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

Shareholders' Equity (Details Textual)																	1 Months Ended													12 Months Ended
Shareholders' Equity (Details Textual)	Dec. 11, 2014 shares	Dec. 12, 2013 shares	Dec. 11, 2013 shares	Dec. 07, 2013 shares	Jun. 20, 2013 € / shares shares	Jun. 20, 2013 $ / shares shares	Dec. 10, 2012 shares	Dec. 06, 2012 shares	Mar. 13, 2012 USD ($) $ / shares shares	Dec. 07, 2011 shares	Jun. 24, 2011 € / shares shares	Jun. 24, 2011 $ / shares shares	Dec. 06, 2010 shares	Jun. 25, 2010 € / shares shares	Jun. 25, 2010 $ / shares shares	Dec. 11, 2009 shares	Jun. 24, 2014 € / shares shares	Jun. 24, 2014 $ / shares shares	Jun. 30, 2013 € / shares	Jun. 30, 2013 $ / shares	Dec. 31, 2012 shares	Jul. 31, 2012	Dec. 31, 2011 shares	Jun. 30, 2011 € / shares	Jun. 30, 2011 $ / shares	Dec. 31, 2010	Jun. 30, 2010 € / shares	Jun. 30, 2010 $ / shares	Jan. 31, 1997	Dec. 31, 2014 USD ($) $ / shares shares	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2007	Sep. 30, 2014 shares	Aug. 31, 2013 shares	Jul. 31, 2013 shares	Jul. 31, 2011 shares
Class of Stock [Line Items]
Number Of Warrants Authorized For Subscription					270,000	270,000					350,000	350,000		250,000	250,000		300,000	300,000
Warrants Subscription Price \| (per share)					€ 0.43	$ 0.57					€ 0.47	$ 0.67		€ 0.70	$ 0.90		€ 0.89	$ 1.22
Share Purchase Price \| (per share)																	€ 10.94	$ 14.87	€ 4.58	$ 6.14				€ 3.54	$ 5.03		€ 5.44	$ 6.68
Social Contribution																													45.00%
Additional Social Security Contribution																																	10.00%
Percentage Of Share Price																																	25.00%
Contribution Rate																										14.00%
Accumulated Statutory Deficit \| $																														$ 148,400,000
Increased Contribution Rate																						30.00%
Warrants Exercised																														200,000
Warrants Cancelled																														50,000
Warrants Subscribed																																		298,000		180,000	300,000
Stock Issued During Period, Value, Acquisitions \| $																														$ 13,050,000
Stock Issued During Period, Value, New Issues \| $																														$ 6,025,000	$ 399,000	$ 601,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term																														10 years
Maximum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term																														4 years
IPO [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues																														12,400,000
Shares Issued, Price Per Share \| $ / shares																														$ 9.75
Payment Of Commission Price Per Share \| $ / shares																														$ 0.585
Stock Issued During Period, Value, New Issues \| $																														$ 113,600,000
Stockholders' Equity, Period Increase (Decrease) \| $																														115,200,000
Payments of Stock Issuance Costs \| $																														700,000
Tax Relief \| $																														$ 2,400,000
Private Placement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Acquisitions																														1,026,364
Shares Issued, Price Per Share \| $ / shares																														$ 12.71
Stock Issued During Period, Value, Acquisitions \| $																														$ 13,049,000
Scientific Advisory Board [Member]
Class of Stock [Line Items]
Number Of Warrants Authorized For Subscription					20,000	20,000
Warrants Subscription Price \| (per share)					€ 0.43	$ 0.57
Warrants Subscribed																																			20,000
Warrants One [Member]
Class of Stock [Line Items]
Class Of Warrant Or Right Exercisable									2,200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares									$ 7.44
Warrants Two [Member]
Class of Stock [Line Items]
Class Of Warrant Or Right Exercisable									1,100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares									$ 11.00
Eclat Pharmaceuticals [Member]
Class of Stock [Line Items]
Warrants Issued During Period Warrants New Issues \| $									$ 3,300,000
Free Share Awards [Member]
Class of Stock [Line Items]
Options authorized Free of Charge Share Award Granted and Outstanding																	250,000	250,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	188,300	192,500					189,700			200,000			230,000			295,000
Stock Issued During Period, Shares, New Issues	150,600			137,150				208,150													45,000		267,400
Free Share Awards [Member] \| Issue One [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues			10,000
Free Share Awards [Member] \| Issue Two [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	6,000
Restricted Stock [Member]
Class of Stock [Line Items]
Options authorized Free of Charge Share Award Granted and Outstanding					200,000	200,000

Income taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]
Income (loss) before income taxes	$ (90,331)	$ (57,753)	$ (9,469)
France [Member]
Income Taxes [Line Items]
Income (loss) before income taxes	(392)	(3,889)	(15,755)
United States [Member]
Income Taxes [Line Items]
Income (loss) before income taxes	$ (89,939)	$ (53,864)	$ 6,286

Income taxes (Details 1) - USD ($) $ in Thousands	12 Months Ended
Income taxes (Details 1) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]
Income tax benefit (provision) computed at the statutory rate (US & France)	$ 36,106	$ 22,842	$ 2,737
Deferred Tax Allowance	(10,973)	(1,930)	(5,251)
Business Tax	(1,400)	(76)	(59)
Non Taxable remeasurement of fair value accounting of earn out	(22,326)	(9,592)	7,303
Total	$ 1,407	$ 11,244	$ 4,729

Income taxes (Details 2) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred income tax assets:
Net taxable operating loss carry-forwards (not utilized)	$ 66,167	$ 81,769	$ 65,657
Other deferred income tax assets	1,052	1,898	3,656
Valuation allowance	(57,980)	(69,940)	(64,356)
Net deferred income tax assets	9,238	13,728	4,957
Deferred income tax liabilities	(9,238)	(16,534)	(19,086)
Deferred income taxes, net	$ 0	$ (2,806)	$ (14,130)

Income taxes (Details 3) $ in Thousands	Dec. 31, 2014 USD ($)
Income Taxes [Line Items]
Total current portion	$ 5,930
2015 [Member]
Income Taxes [Line Items]
Total current portion	$ 5,930

Income taxes (Details Textual) - USD ($)	12 Months Ended
Income taxes (Details Textual) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]
Income tax	$ (1,407,000)	$ (11,244,000)	$ (4,729,000)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential	40.00%
Percentage Of Valuation Allowance	100.00%
Description Of Annual Utilization, Operating Loss Carry Forward	Annual utilization is normally limited to 1,000,000 plus fifty per cent (50%) of any taxable income in excess of this threshold.
Pre Acquisition Tax Loss	$ 4,900,000
Pre Acquisition Tax Loss Per Year	$ 1,800,000
Description Of Substantial Change In Operations For Income Tax Rate	Substantial change in operations occurs when the following criteria are met: Reduction of more than fifty per cent (50%) in revenues from one fiscal year to another, Reduction of more than fifty per cent (50%) in the average employees employed or in the gross book value of assets from one fiscal year to another.
Decrease In Operating Loss Carry Forwards	$ 69,300,000
Decrease In Operating Loss Carry Forwards Utilized	35,300,000
Increase In Operating Loss Carry Forwards	10,200,000
Net Income Tax Payable	7,600,000
Accrued Income Taxes	11,700,000
Deferred Income Tax Expense (Benefit)	14,100,000
Prepaid Taxes	1,000,000
Long Term Assets Taxes	$ 13,100,000
Deferred Tax Amortized Life	14 years 3 months 18 days
Deferred Tax Amortized Rate	7.00%
Tax Relief Amount	$ 9,700,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	5,900,000
Research Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Accrued Income Taxes	5,500,000
General Business Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Accrued Income Taxes	$ 1,500,000
France [Member]
Income Taxes [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential	33.33%
Operating Loss Carryforwards	$ 142,200,000
United States [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	46,900,000
French Government [Member]
Income Taxes [Line Items]
Income tax	$ 1,400,000	$ 76,000	$ 29,000

Employee Retirement plans (Details)	12 Months Ended
Employee Retirement plans (Details)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Retirement Plans [Line Items]
Average increase of salaries	3.00%	3.00%	3.00%
Discounted interest rate	1.49%	3.25%	3.00%
Turn over	actuarial standard and average of the last 5 years	actuarial standard and average of the last 5 years	actuarial standard and average of the last 5 years
Age of retirement	60 to 65 years actuarial standard based on age and professional status	60 to 65 years actuarial standard based on age and professional status	60 to 65 years actuarial standard based on age and professional status

Employee Retirement plans (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Retirement Plans [Line Items]
Benefit obligations at beginning of year	$ 2,142	$ 1,159
Service cost	99	1,106
Interest cost	36	36
Plan amendments	0	0
Benefits paids	(87)	0
Actuarial loss (gain)	460	(233)
Exchange rate changes	(300)	74
Benefit obligations at end of year	$ 2,350	$ 2,142

Employee Retirement plans (Details 2) $ in Thousands	Dec. 31, 2014 USD ($)
Employee Retirement Plans [Line Items]
Defined Benefit Plan, Expected Future Benefit Payments, 12/31/2015	$ 55
Defined Benefit Plan, Expected Future Benefit Payments, 12/31/2016	0
Defined Benefit Plan, Expected Future Benefit Payments, 12/31/2017	0
Defined Benefit Plan, Expected Future Benefit Payments, 12/31/2018	0
Defined Benefit Plan, Expected Future Benefit Payments, 12/31/2019	12
Defined Benefit Plan, Expected Future Benefit Payments, Next 5 Years	$ 150

Employee Retirement plans (Details Textual) - USD ($)	12 Months Ended
Employee Retirement plans (Details Textual) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Retirement Plans [Line Items]
Defined Contribution Plan, Cost Recognized	$ 719,000	$ 701,000	$ 815,000
Defined Benefit Plan, Benefit Obligation	$ 2,350,000	$ 2,142,000	$ 1,159,000
Defined Contribution Plan, Employer Matching Contribution, Percent			25.00%
Defined Contribution Plan Employer Contribution			$ 49,000
Defined Contribution Plan, Employer Discretionary Contribution Amount			$ 140,000

Fair value of financial instruments (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Assets

Cash and cash equivalents

$ 39,760

$ 6,636

$ 2,742

$ 3,456

Marketable securities

53,074

401

$ 6,413

Operational Gain Loss On Fair Value Assets Hedges Recognized In Earnings

Financial Gain Loss On Fair Value Assets Hedges Recognized In Earnings

547

Operational And Financial Gain Loss On Fair Value Assets Hedges Recognized In Earnings

547

Liabilities

Operational Gain Loss On Fair Value Hedges Recognized In Earnings

(60,503)

(28,135)

Financial Gain Loss On Fair Value Hedges Recognized In Earnings

(3,525)

(1,991)

Operation And Financial Gain Loss On Fair Value Hedges Recognized In Earnings

(64,028)

(30,126)

Cash and Cash Equivalents [Member]

Assets

Cash and cash equivalents

39,760

6,636

Operational Gain Loss On Fair Value Assets Hedges Recognized In Earnings

Financial Gain Loss On Fair Value Assets Hedges Recognized In Earnings

Operational And Financial Gain Loss On Fair Value Assets Hedges Recognized In Earnings

Marketable Securities [Member]

Assets

Marketable securities

53,074

401

Operational Gain Loss On Fair Value Assets Hedges Recognized In Earnings

Financial Gain Loss On Fair Value Assets Hedges Recognized In Earnings

547

Operational And Financial Gain Loss On Fair Value Assets Hedges Recognized In Earnings

547

Fair Value, Inputs, Level 1 [Member] | Cash and Cash Equivalents [Member]

Assets

Cash and cash equivalents

39,760

6,636

Fair Value, Inputs, Level 1 [Member] | Marketable Securities [Member]

Assets

Marketable securities

53,074

401

Fair Value, Inputs, Level 2 [Member] | Cash and Cash Equivalents [Member]

Assets

Cash and cash equivalents

Fair Value, Inputs, Level 2 [Member] | Marketable Securities [Member]

Assets

Marketable securities

Fair Value, Inputs, Level 3 [Member] | Cash and Cash Equivalents [Member]

Assets

Cash and cash equivalents

Fair Value, Inputs, Level 3 [Member] | Marketable Securities [Member]

Assets

Marketable securities

Acquisition Liability Contingent Consideration [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[1]

70,112

37,991

Operational Gain Loss On Fair Value Hedges Recognized In Earnings

^[1]

(33,445)

(14,768)

Financial Gain Loss On Fair Value Hedges Recognized In Earnings

^[1]

Gain (Loss) on Fair Value Hedges Recognized in Earnings

^[1]

(33,445)

Operation And Financial Gain Loss On Fair Value Hedges Recognized In Earnings

^[1]

(14,768)

Acquisition Liability Contingent Consideration [Member] | Fair Value, Inputs, Level 1 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[1]

Acquisition Liability Contingent Consideration [Member] | Fair Value, Inputs, Level 2 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[1]

Acquisition Liability Contingent Consideration [Member] | Fair Value, Inputs, Level 3 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[1]

70,112

37,991

Acquisition Liability Note [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[2]

10,405

Operational Gain Loss On Fair Value Hedges Recognized In Earnings

^[2]

(3,013)

(5,027)

Financial Gain Loss On Fair Value Hedges Recognized In Earnings

^[2]

Gain (Loss) on Fair Value Hedges Recognized in Earnings

^[2]

(3,013)

Operation And Financial Gain Loss On Fair Value Hedges Recognized In Earnings

^[2]

(5,027)

Acquisition Liability Note [Member] | Fair Value, Inputs, Level 1 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[2]

Acquisition Liability Note [Member] | Fair Value, Inputs, Level 2 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[2]

Acquisition Liability Note [Member] | Fair Value, Inputs, Level 3 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[2]

10,405

Acquisition Liability Warrant Consideration [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[3]

34,542

10,497

Operational Gain Loss On Fair Value Hedges Recognized In Earnings

^[3]

(24,045)

(8,340)

Financial Gain Loss On Fair Value Hedges Recognized In Earnings

^[3]

Gain (Loss) on Fair Value Hedges Recognized in Earnings

^[3]

(24,045)

Operation And Financial Gain Loss On Fair Value Hedges Recognized In Earnings

^[3]

(8,340)

Acquisition Liability Warrant Consideration [Member] | Fair Value, Inputs, Level 1 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[3]

Acquisition Liability Warrant Consideration [Member] | Fair Value, Inputs, Level 2 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[3]

Acquisition Liability Warrant Consideration [Member] | Fair Value, Inputs, Level 3 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[3]

34,542

10,497

Deerfield Royalty Agreement [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[4]

6,837

4,590

Operational Gain Loss On Fair Value Hedges Recognized In Earnings

^[4]

Financial Gain Loss On Fair Value Hedges Recognized In Earnings

^[4]

(2,386)

(1,991)

Gain (Loss) on Fair Value Hedges Recognized in Earnings

^[4]

(2,386)

Operation And Financial Gain Loss On Fair Value Hedges Recognized In Earnings

^[4]

(1,991)

Deerfield Royalty Agreement [Member] | Fair Value, Inputs, Level 1 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[4]

Deerfield Royalty Agreement [Member] | Fair Value, Inputs, Level 2 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[4]

Deerfield Royalty Agreement [Member] | Fair Value, Inputs, Level 3 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[4]

6,837

4,590

Broadfin Royalty Agreement [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[5]

3,259

2,187

Operational Gain Loss On Fair Value Hedges Recognized In Earnings

^[5]

Financial Gain Loss On Fair Value Hedges Recognized In Earnings

^[5]

(1,139)

Gain (Loss) on Fair Value Hedges Recognized in Earnings

(1,139)

Operation And Financial Gain Loss On Fair Value Hedges Recognized In Earnings

^[5]

Broadfin Royalty Agreement [Member] | Fair Value, Inputs, Level 3 [Member]

Liabilities

Business Acquisition Contingent Consideration Net

^[5]

$ 3,259

$ 2,187

[1]	Acquisition liability deferred consideration: the fair value is estimated using a discounted cash flow model based on probability adjusted projected annual gross profit of each of the products which formed the project portfolio at the time of acquisition of Éclat Pharmaceuticals (Note 16 Long Term Debt). The fair value of the deferred consideration will change over time in accordance with the changes in market conditions and thus business plan projections as the relate to market size, market share, product pricing, competitive landscape, gross profit margins expected for each of the products.
[2]	Acquisition liability Note: the Company uses a probability-weighted discounted cash flow model (see note 16 Long Term Debt).
[3]	Acquisition liability warrant consideration: the Company uses a Black-Scholes option pricing model. The fair value of the warrant consideration will change over time depending on the volatility and share price at balance sheet date (see note 16 Long Term Debt).
[4]	Deerfield Royalty Agreement: the fair value is estimated using a discounted cash flow model based on probability adjusted projected annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals (see Note 16 Long Term Debt).
[5]	Broadfin Royalty Agreement: the fair value is estimated using a discounted cash flow model based on probability adjusted projected annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals (see Note 16 Long Term Debt).

Fair value of financial instruments (Details 1) - Fair Value, Inputs, Level 3 [Member] - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value Of Financial Instruments [Line Items]
Liability recorded upon acquisition	$ (58,893)		$ (50,927)
Operational gain (loss) recognized in earnings	(60,503)	$ (28,135)	$ 18,993
Payment For Reimbursements	12,000
Payment deferred consideration (Hycet)	1,354	841
Payment interest on acquisition liability note	1,389	335
Net carrying value	(104,653)	(58,893)
Deerfield Royalty agreement [Member]
Fair Value Of Financial Instruments [Line Items]
Liability recorded upon acquisition	(2,600)
Interest expense recognized in earnings	(2,386)	(1,990)
Payment of Royalty	140
Net carrying value	(6,837)	(2,600)
Broadfin Royalty agreement [Member]
Fair Value Of Financial Instruments [Line Items]
Liability recorded upon acquisition	(2,187)
Interest expense recognized in earnings	(1,139)	0
Payment of Royalty	67
Net carrying value	$ (3,259)	$ (2,187)

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2014 USD ($)
Commitments And Contingencies [Line Items]
2015	$ 841
2016	177
TOTAL	$ 1,018

Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Commitments And Contingencies [Line Items]
Operating Leases, Rent Expense, Net	$ 844,000	$ 759,000	$ 863,000
Generic Pharmaceutical Product [Member]
Commitments And Contingencies [Line Items]
Purchase Obligation	46,000
Recipharm AB [Member]
Commitments And Contingencies [Line Items]
Long-term Purchase Commitment, Amount	$ 22,500,000
Long-term Purchase Commitment, Period	5 years

Industry and geographic information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue:
Revenues	$ 14,775	$ 4,179	$ 7,534
USA [Member]
Revenue:
Revenues	14,302	3,368	3,894
Europe [Member]
Revenue:
Revenues	$ 473	$ 811	$ 3,640

Industry and geographic information (Details 1) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Long-lived assets:
Long Lived Assets	$ 48,780	$ 61,175	$ 92,226
USA [Member]
Long-lived assets:
Long Lived Assets	47,077	58,868	60,260
France [Member]
Long-lived assets:
Long Lived Assets	$ 1,703	$ 2,307	$ 31,966

Industry and geographic information (Details Textual) - USD ($)	1 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Industry And Geographic Information [Line Items]
Revenues	$ 11,920,000	$ 983,000	$ 560,000

Related Party Transactions (Details Textual) - USD ($)				1 Months Ended	12 Months Ended
Related Party Transactions (Details Textual) - USD ($)	Dec. 03, 2013	Feb. 04, 2013	Mar. 13, 2012	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Percentage Of Earn Out Payment					20.00%
Contingent Potential Cash Payment						$ 1,000,000
Debt Financing Facility Agreement Amount	$ 5,000,000
Business Combination Commitment Percentage						100.00%
Secured Debt					$ 12,000,000
Costs and Expenses, Related Party					$ 3,013,000		$ 0
Repayments of Secured Debt				$ 12,000,000
Royalty Agreement [Member]
Long Term Debt Repayment Percentage	0.834%	1.75%
Debt Repayment Term	Dec. 31, 2024	Dec. 31, 2024
Facility Agreement [Member]
Debt Financing Facility Agreement Amount		$ 15,000,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 15,000,000
Line Of Credit Facility Initial Loan	5,000,000
Line Of Credit Facility Additional Loan	$ 5,000,000
Line of Credit Facility, Interest Rate During Period	12.50%	12.50%
Costs and Expenses, Related Party		$ 112,500
Eclat Pharmaceuticals [Member]
Warrants Issued During Period Warrants New Issues			$ 3,300,000
Percentage Of Earn Out Payment			20.00%
Business Combination Commitment Percentage			20.00%
Eclat Pharmaceuticals [Member] \| Senior Secured Six Year Note [Member]
Warrants Issued During Period Warrants New Issues			$ 3,300,000
Secured Debt			$ 12,000,000

Post Balance Sheet Events (Details Textual) $ in Millions		1 Months Ended
Post Balance Sheet Events (Details Textual) $ in Millions	Jan. 15, 2015 $ / Product	Feb. 15, 2015 USD ($)
Post Balance Sheet Events [Line Items]
Wholesalers Receive Chargeback Amount For Units Sold \| $		$ 19.0
Minimum [Member]
Post Balance Sheet Events [Line Items]
Per Vial Rate (USD $) in Wholesale Acquisition Cost	35.80
Maximum [Member]
Post Balance Sheet Events [Line Items]
Increased Per Vial Rate (USD $) in Wholesale Acquisition Cost	98.75